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Abstract 
Genome-wide association studies (GWAS) have found few common variants that influence 
fasting measures of insulin sensitivity. We hypothesized that a GWAS of an integrated 
assessment of fasting and dynamic measures of insulin sensitivity would detect novel common 
variants. We performed GWAS of the modified Stumvoll Insulin Sensitivity Index (ISI) within 
the Meta-Analyses of Glucose and Insulin-related traits Consortium. Discovery was performed in 
16,753 individuals, and replication was attempted for the 23 most significant novel loci in 13,354 
independent individuals. Association with ISI was tested in models adjusted for age, sex, body 
mass index (BMI) and in a model (“Model 3”) analyzing the combined influence of the genotype 
effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. In 
Model 3, three variants reached genome-wide significance: rs13422522 (NYAP2, P=8.87 ×10
-11
), 
rs12454712 (BCL2, P=2.7×10
-8
) and rs10506418 (FAM19A2, P=1.9×10
-8
). The association at 
NYAP2 was eliminated by conditioning on the known IRS1 insulin sensitivity locus; the BCL2 
and FAM19A2 associations were independent of known cardio-metabolic loci. In conclusion, we 
identified two novel loci and replicated known variants associated with insulin sensitivity. 
Further studies are needed to clarify the causal variant and function at the BCL2 and FAM19A2 
loci. 
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 Genome-wide association studies (GWAS) have identified common genetic variants that 
influence risk of type 2 diabetes (1), a disease marked by reduction in beta-cell function and 
insulin sensitivity (2). While both beta-cell function and insulin sensitivity traits are partly 
heritable, GWAS have demonstrated relatively few single nucleotide variants (SNPs) associated 
with insulin sensitivity (3). 
 
Traits used to estimate insulin sensitivity from fasting measurements in prior large GWAS, 
including fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-
IR), demonstrate approximately half the heritability of traits that incorporate both fasting and 
dynamic assessment of insulin sensitivity following a glucose load (4). Moreover, there is only 
modest genetic correlation between HOMA-IR and measures of insulin sensitivity by 
euglycemic clamp, which is considered the gold standard measure of peripheral insulin 
sensitivity (5,6). Thus, an alternative approach to discover new common genetic variants 
associated with insulin sensitivity is to perform GWAS using a dynamic measure of whole-body 
insulin sensitivity. As an example, a recent GWAS identified a novel insulin sensitivity locus at 
NAT2 using euglycemic clamp and insulin suppression test techniques in 2,764 subjects with 
replication in another 2,860 individuals (7). However, these direct, whole-body measures of 
insulin sensitivity are time- and resource-intensive interventions, which limits the feasible 
sample size of such experiments. Derived indices from an oral glucose tolerance test (OGTT) 
that integrate fasting and dynamic measures of insulin sensitivity reasonably approximate 
euglycemic clamp measures and can be applied in existing large cohorts with glycemic traits, 
potentially increasing the statistical power to detect novel variant associations.  
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 We tested the hypothesis that a well-powered GWAS would detect common genetic variants for 
the modified Stumvoll Insulin Sensitivity Index (ISI). Insulin sensitivity assessed by the 
euglycemic hyperinsulinemic clamp (M/I) has a stronger correlation with the ISI than with 
HOMA-IR (r=0.79 vs. r=0.59, respectively) (8). In addition, the ISI is well correlated (r=0.69) 
with M/I even when calculated using only fasting insulin values and glucose and insulin values 
at 120 minutes after a 75-gram oral glucose load (9); this modified version is widely available in 
existing cohorts providing a larger sample size for association analyses than the sample size that 
would be available if indices requiring additional time points were used. We further 
hypothesized that a subset of these common genetic variants would influence the ISI 
independently or through their effect on body mass index (BMI). Thus, we tested the association 
of the modified ISI in statistical models without adjustment for BMI, with adjustment for BMI, 
and in a validated model (10,11) analyzing the combined influence of the genotype effect 
adjusted for BMI and the interaction effect between the genotype and BMI on ISI.  
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 Research Design and Methods 
Cohort Descriptions 
The cohorts participating in the Meta-Analyses of Glucose and Insulin-related traits Consortium 
(MAGIC) contributed a total of 30,107 individuals to the analyses. Detailed information on the 
study cohorts and methods is provided in Supplemental Table 1. All participants were of white 
European ancestry from the United States or Europe and were free of diabetes. All studies were 
approved by local research ethic committees, and all participants gave informed consent.  
 
Modified Stumvoll Insulin Sensitivity Index (ISI) 
Missing trait data were not imputed, and outliers were not excluded from analyses. The ISI was 
calculated as previously described (9) according to the following formula: 
0.156-(0.0000459*insulin2hrs[pmol/L])-(0.000321*insulinfasting [pmol/L))- (0.0054* glucose2hrs [mmol/L]) 
 
Discovery Effort: Genome-Wide Association Studies 
Cohorts that were able to contribute genome-wide genotyping results during the course of the 
project were included in the discovery effort. These were: FHS, Sorbs, FUSION, CHS, LURIC, 
ULSAM, and METSIM. For the discovery GWAS, all samples with call-rates < 95% were 
excluded, and SNPs departing from Hardy-Weinberg Equilibrium (at P < 10
-6
), genotype-rate < 
95%, or minor allele frequency (MAF) < 1% were excluded. Poorly imputed SNPs were 
excluded if R
2
 < 0.3 or proper-info was < 0.4.  
 
Each SNP was tested for association with ISI in three different additive genetic models: Model 1 
was adjusted for age and sex; Model 2 was adjusted for age, sex, and BMI; and Model 3 analyzes 
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 the combined influence of the genotype effect adjusted for BMI and the interaction effect 
between the genotype and BMI on ISI (10,11). The associations in Model 3 result from a test 
with two degrees of freedom. When no interaction is present, the additional degree of freedom 
results in a modest loss of statistical power. However, when interaction is present, statistical 
power of the model is greater (11). To adjust for differences in insulin measurement between 
cohorts, effect estimates were normalized to the standard deviation (SD) of the ISI in each cohort 
(Supplemental Table 1). A robust estimate of the standard error was calculated in the 
interaction analysis using ProbAbel, QUICKtest or Generalized Estimating Equations (GEE) 
using the R geepack package. An inverse variance meta-analysis using METAL was performed 
on the beta/SD from each cohort.   
 
Following meta-analysis, SNPs with total sample size less than 8,500 (~1/2 of the maximum 
sample size), or with heterogeneity P-values ≤ 10
-6
 (a value chosen to take into account multiple 
hypothesis testing but below the level of strict Bonferroni correction) in the meta-analysis of the 
discovery cohorts were removed. Genomic correction of cohort-specific association statistics 
(i.e., correction for each individual study) was performed. In total, up to 2.4 million SNPs were 
meta-analyzed for association with ISI in the discovery effort.  
 
Selection of SNPs for Replication 
Candidate SNPs for replication were identified by their association P-value ≤ 10
-7
 in one or more 
of the analysis models. For gene loci with multiple replication candidates, the SNP with the 
lowest P-value and any other SNP in low linkage disequilibrium (LD, r
2 
<0.5) with the index 
SNP in Europeans were retained. Using these filters, 23 unique candidate SNPs from 23 loci 
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 were identified for replication. The SNP Annotation and Proxy Search (SNAP) site was used to 
find up to three proxies in high LD (r
2
 > 0.8) in Europeans for each candidate SNP.   
 
Replication Effort 
Cohorts that did not contribute to the discovery effort but were able to contribute association 
results during the course of the project were included in the replication effort. These were: 
EUGENE2, Amish, RISC, Tuebingen, Inter99, Segovia, Pizarra, Botnia, 1936 Birth Cohort, and 
Ely Study. Genotype data were obtained using in silico data from pre-existing GWAS or de novo 
genotyping. In replication cohorts, SNPs with minor allele count (MAC) < 20 were excluded. 
Additional details of the replication cohort effort are provided in Supplemental Table 1. 
 
Combined meta-analysis 
We required the absence of heterogeneity in the combined analysis of discovery and replication 
cohorts (P > 10
-6
) as well as nominal significance (P < 0.05) in the replication effort and 
genome-wide significance (P < 5×10
-8
) in the combined meta-analysis for statistical evidence of 
association between a novel SNP and the ISI. To assess the effect of removing lower frequency 
SNPs in Model 3, a sensitivity analysis was performed using the MAC < 20 filter on a cohort-
wise basis in both the discovery and replication cohorts.  
 
Assessment for association of known insulin sensitivity loci with ISI 
The associations of published insulin sensitivity loci were tested for association with the ISI in 
the discovery cohorts. Loci associated with fasting insulin without (12) and with adjustment for 
BMI (3,12), with fasting insulin using the approach in Model 3 (10), and with direct measures of 
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 insulin sensitivity were included in these analyses (7). The published results for associations with 
fasting insulin with or without BMI adjustment (N ≈ 50,000-100,000) (3,12) or exploiting 
potential BMI by gene interaction (Model 3, N ≈ 80,000) (10) used the same statistical approach 
as in the current study but were derived in a sample size approximately 3-6 times larger than that 
of the current study discovery cohort (N ≈16,000). The sample sizes of the published fasting 
insulin analyses were much greater as only fasting insulin and BMI were required phenotypes for 
cohort participation. To perform analyses of association with fasting insulin and ISI in a 
comparable sample, we also examined the subset of discovery cohorts that contributed to the 
current assessment of ISI and prior assessments of fasting insulin: FHS, Sorbs, FUSION, and 
CHS. In Model 2 and Model 3, only data from FHS, Sorbs, and FUSION were analyzed as 
participant level BMI data were not available in CHS. A binomial sign test was used to 
determine whether the expected direction of effect for these published loci with ISI occurred 
more often than by chance.  
 
Conditional analyses and assessment for association of top findings with direct measures of 
insulin sensitivity 
Findings that reached genome-wide significance were assessed for association with direct 
measures of insulin sensitivity in the GENEtics of Insulin Sensitivity (GENESIS) consortium 
(7). Direct measures of insulin sensitivity were inverse normal transformed M value in cohorts 
with euglycemic insulin clamp assessments and inverse normal transformation of the steady state 
plasma glucose from cohorts with insulin suppression test. These two traits are highly correlated 
(r= -0.85, P<0.001) (13), and tests of association with the direct measure of insulin sensitivity 
showed no evidence of heterogeneity (P-value for heterogeneity =0.34 for the BCL2 variant and 
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 P- value for heterogeneity =0.66 for the FAM19A2 variant). Therefore, we did not perform 
separate tests of association in the smaller subsets of data with either the M value or insulin 
suppression test phenotype. Statistical models were adjusted for age, gender, and BMI.  
 
The top findings of the ISI analyses were also assessed in a MAGIC association analysis from 
Manning and colleagues (10) with fasting insulin using the approach in Model 3. These ISI 
variants were only available in the discovery cohort from Manning and colleagues (N=38,649 for 
rs12454712 and N=45,290 for rs10506418). To perform association analyses with fasting insulin 
and ISI in a comparable sample, we also performed association analyses with fasting insulin and 
ISI in a subset of the discovery cohort: FHS, Sorbs, and FUSION.  
 
Approximate conditional analyses were performed to understand whether known loci contributed 
to the associations of novel findings with the ISI (14). These analyses were based on the 
summary level statistics from the meta-analysis and the estimated LD using individual-level 
genotype data from the Framingham Heart Study discovery cohort. The software implementation 
for this approach does not incorporate the interaction term from Model 3, and therefore 
conditional analyses were not performed in Model 3.  
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 Results 
The demographic characteristics of the participants included in the discovery and replication 
efforts are presented in Table 1. In total, the discovery, replication, and combined meta-analyses 
included up to 16, 753; 13,354; and 30,107 participants, respectively.  
 
Using a variance component approach implemented in the software SOLAR (15), the heritability 
of the ISI (H2r ± SE) in related Framingham Heart Study participants (n=2,833) was very similar 
without or with adjustment for BMI (34.6 ± 6.8%, P= 2.8 ×10
-8
 and 33.4 ± 6.8%, P= 1.0 ×10
-6 
respectively). Within the ULSAM discovery cohort, the Spearman correlation between the ISI 
and M value from the euglycemic hyperinsulinemic was 0.71, (Figure 1) consistent with reports 
from the literature (9); the Spearman correlation between ISI and fasting insulin was -0.49 
(Figure 1).  
 
When tested in the full discovery cohort, 12 of 13 loci previously associated with fasting insulin 
in the literature (12) (P=0.002 for binomial sign test) and 13 of 15 loci previously associated 
with fasting insulin after adjustment for BMI in the literature (3,12) (P=0.004 for binomial sign 
test) showed the expected direction of effect with the ISI in the discovery cohorts (Supplemental 
Table 2). When these associations were examined in a subset of the current study discovery 
cohort (Supplemental Table 2), statistical significance was reduced but effects at each loci 
remained in the expected direction (10 of 13 loci for ISI vs. fasting insulin without BMI 
adjustment, P=0.03 for binomial sign test and 11 of 15 loci for ISI vs. fasting insulin with BMI 
adjustment, P=0.04 for binomial sign test). Using a variant in LD with rs1208 (rs7815686, r
2
 = 
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 0.67), we also found the expected direction of effect with ISI in the discovery cohorts (n=16,753) 
at the NAT2 locus (Model 1, β= -0.029, P=9×10
-3
) (7).  
 
The QQ plots for Models 1, 2, and 3 are shown in Supplemental Figure 1, 2, and 3, 
respectively. Measures of genomic control were consistent with low inflation (Model 1 λGC= 
1.015; Model 2 λGC= 1.006; Model 3 λGC= 1.079). While genomic control was used to correct 
for each individual study, no additional corrections were applied to the meta-analysis results. The 
results of the discovery and replication results, separately, for Model 1 (with age- and sex-
adjustment), Model 2 (with age-, sex-, and BMI- adjustment), and Model 3 (with age-, sex-, and 
BMI- adjustment and analyzing the combined influence of the genotype effect adjusted for BMI 
and the interaction effect between the genotype and BMI on ISI) are shown in Supplemental 
Table 3. Four SNPs selected from the discovery effort reached nominal significance (P <0.05) in 
the replication analyses: rs13422522 (NYAP2) in Models 1, 2, and 3; rs12454712 (BCL2) in 
Models 2 and 3; rs10506418 (FAM19A2) in Model 3; rs6013915 (PFDN4) in Model 3. Although 
the association with rs4548846 (CDH13) reached nominal significance in the replication effort 
for Model 3, the association was in the opposite direction of effect as in the discovery analyses; 
consequently, the association of this variant also had high heterogeneity combined meta-analysis.  
 
We compared the beta coefficients for the 22 SNPs identified in the discovery effort (rs4548846, 
CDH13 was excluded given high heterogeneity) with fasting insulin and ISI in a subset of the 
discovery cohort. Pearson correlations between the beta for fasting insulin and the beta for ISI 
were -0.494 in Model 1, -0.797 in Model 2, and -0.461 (for SNP effect) and -0482 (for 
interaction) in Model 3.  
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The results of the combined discovery and replication cohort meta-analyses in each of the three 
models are shown in Table 2 and in Supplemental Table 3. No association reached genome-
wide significance in Model 1. In Model 2, rs13422522 (NYAP2, P=1.8 ×10
-11
) and rs12454712 
(BCL2, P=1.9×10
-8
) achieved genome-wide significance. In Model 3, rs13422522 (NYAP2, 
P=8.9×10
-11
), rs12454712 (BCL2, P=2.7×10
-8
), and rs10506418 (FAM19A2, P=1.9×10
-8
) 
reached genome-wide significance. In Model 3, rs6027072 (ARHGAP40, P=4.4×10
-9
) also 
reached genome-wide significance but had not achieved nominal significance in the replication 
cohort, and rs6013915 (PFND4) had high heterogeneity in the combined meta-analysis of 
discovery and replication cohorts (heterogeneity P = 6.03×10
-7
); therefore associations with these 
SNPs were not included as trustworthy findings. 
 
 
Hence, rs13422522 (NYAP2), rs12454712 (BCL2) and rs10506418 (FAM19A2) were the three 
SNPs that reached our a priori requirements for claiming statistical evidence. The association at 
rs13422522 (NYAP2) was in LD (r
2
 = 0.7) with previously reported results at the known insulin 
sensitivity signal rs2943641 (IRS1) (10), and the association with the ISI in Model 2 was greatly 
reduced by conditioning on the published SNP in the discovery cohort (beta = -0.066 ± 0.01, P= 
4.29 × 10
-8
 to beta = -0.025 ± 0.01, P=0.01). Thus, this SNP was considered a reflection of the 
known IRS1 signal and not an independent signal. The associations for rs12454712 (BCL2) and 
rs10506418 (FAM19A2) with the ISI were consistent across the discovery and replication cohorts 
(Supplemental Figure 4 and Supplemental Figure 5, respectively). When stratifying by BMI, 
the effect of the minor (A) allele at rs10506418 (FAM19A2) on insulin sensitivity was negative 
at lower BMI and became positive and stronger with increasing BMI (Figure 2), and the effect 
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 of the major (T) allele at rs12454712 (BCL2) on ISI was more negative with increasing BMI 
(Figure 3). 
 
The genomic inflation of Models 1 and 2 was low and slightly higher in Model 3. Because the 
same individuals were used in each model, inflation in Model 3 was unlikely to arise from 
population stratification. We performed an additional sensitivity analysis that applied the MAC < 
20 filter on a cohort-wise basis to both discovery and replication cohorts (Supplemental Table 
4), which tended to reduce the statistical significance of associations with high heterogeneity and 
slightly reduced the statistical significance of the association at the FAM19A2 locus in Model 3 
without markedly reducing the magnitude of effect or affecting heterogeneity (beta = -0.62 ± 
0.13, P-value = 1.9 ×10
-8
, P-value for heterogeneity= 0.11 to beta = -0.58 ± 0.13, P-value =8.0 
×10
-7
, P-value for heterogeneity= 0.07). The sample size for the FAM19A2 locus association in 
Model 3 was 462 individuals fewer when the MAC filter was applied in the discovery cohorts 
versus when the MAF filter was applied, and the resulting loss in power was likely responsible 
for the slight reduction in statistical significance. 
 
Conditioning the results at either variant with known signals at least 1 Mb away did not attenuate 
the association with the ISI in the discovery cohorts of Model 2 (full description in 
Supplemental Table 5). The rs10506418 (FAM19A2) variant was not associated with fasting 
insulin using Model 3 in a separate GWAS result (10) or with direct measures of insulin 
sensitivity in GENESIS. The major (T) allele of rs12454712 (BCL2), which was associated with 
lower insulin sensitivity in this study, was also associated with a trend toward higher fasting 
insulin in a separate GWAS result using Model 3 (SNP effect -0.006 ± 0.003, interaction effect 
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 0.001 ± 0.001, P= 5.9×10
-5
, N=38,649) (10). Similar trends were observed when the variant was 
tested for association with ISI and fasting insulin in the same discovery cohort subset 
(Supplemental Table 5).  
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 Discussion 
In a study of over 30,000 participants, we found novel, independent, genome-wide significant 
associations for the ISI at rs12454712 (BCL2) and rs10506418 (FAM19A2). Strengths of the 
current study’s design include a large sample size, well-phenotyped individuals, high-quality 
genomic data, and use of traditional and contemporary statistical models to account for the 
influence of BMI on insulin sensitivity. In addition, our approach targeted a phenotype not 
previously examined in GWAS: the modified Stumvoll Insulin Sensitivity Index. By 
incorporating glucose and insulin measures before and after a glucose load, this phenotype 
captures information that fasting assessments such as HOMA-IR or insulin, alone would not. 
Indeed, the correlation between ISI and M-value is higher than that between M-value and fasting 
insulin (16), which has been used in prior genetic studies of insulin sensitivity (10,12). At the 
same time, the use of measures obtained at only two time points (fasting and 120 minutes) during 
an OGTT permitted assembly of a large sample size required for adequate statistical power.  
 
Several findings serve as positive controls for our results and demonstrate that the ISI is a robust measure 
of fasting and whole-body insulin sensitivity. First, we observe strong correlation of ISI with direct 
measures of insulin sensitivity. Second, we show that the ISI can detect genetic influences on measures of 
fasting insulin sensitivity (3,10,12), generally ascribed to hepatic physiology, as well as on measures of 
whole-body insulin sensitivity, which also incorporates contributions from muscle and adipose tissue. 
Integrated measures of insulin sensitivity may have clinical relevance as reduction in peripheral 
insulin sensitivity may be an early contributor to type 2 diabetes development (17-19).  
 
Consistent with prior genetic explorations of insulin sensitivity (10), the association of variants at 
the BCL2 and FAM19A2 loci became stronger and genome-wide significant after accounting for 
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 the effect of BMI on ISI. Notably, the ISI can be calculated with or without BMI in the formula, 
and the correlation of the ISI with M/I is greater when BMI is included (r=0.69 vs. r=0.79) (8,9). 
We note that the effect of these loci on insulin sensitivity is modest, consistent with published 
findings on other common genetic variants for glycemic traits, such as glucose (12) and fasting 
insulin (3,10,12). Yet, the findings of the current work are meaningful as they provide a more 
complete understanding of the contribution of common genetic variation to insulin sensitivity. 
 
Existing literature bolsters our finding of BCL2 as a novel candidate insulin sensitivity locus. 
The major (T) allele at rs12454712, which was associated with lower insulin sensitivity in our 
analysis, has been previously associated with type 2 diabetes in a multi-ethnic GWAS (OR = 
1.09, 95% confidence interval (CI), 1.05–1.11, P = 2.1 × 10
−8
) (20) in analyses adjusted for BMI. 
Further, this same variant has recently been associated with higher BMI-adjusted waist-hip ratio 
in women (beta= 0.035, P= 1.1×10
-9
, N= 96,182), but not men (beta= 0.007, P=0.25, N=73,576) 
(22). All these findings suggest the metabolically deleterious effects of the BCL2 locus become 
more evident after adjustment for BMI. Last, we find that the statistical association of 
rs12454712 (BCL2) is stronger with the ISI than with fasting insulin (10). Notably, the published 
fasting insulin results were performed in a study much larger than in the current work. The 
ability of the ISI to detect a genome-wide significant finding in a smaller sample suggests the 
BCL2 locus may have a greater influence on insulin sensitivity when fasting and post-prandial 
phenotypes are assessed together.  
 
The mechanism by which BCL2 influences insulin sensitivity remains unclear. The BCL2 family 
of proteins regulate apoptosis through control of mitochondrial permeability (23). Mouse models 
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 suggest that inhibiting bcl2 improves glucose tolerance through effects on the pancreatic beta 
cells (24). Conversely, pharmacological inhibition of the protein BCL2 causes hyperglycemia 
among a subset of patients with chronic lymphocytic leukemia (25), but the mechanism of this 
observation is unknown. In contrast, there is little direct published literature to support the role of 
FAM19A2 in insulin sensitivity. We found that the association of the minor (A) allele at the 
FAM19A2 locus with reduced insulin sensitivity was detected at BMI < 30 kg/m
2
. This may 
suggest the variant is more deleterious among individuals with lower levels of adiposity. While 
BCL2 and FAM19A2 are the closest genes to rs12454712 and rs10506418, respectively, we have 
not excluded other genes in the region (Supplemental Figure 6 and 7). Additional in silico 
findings at the BCL2 and FAM19A2 variants are provided in Supplemental Table 5.  
 
We recognize limitations to our study. First, analyses were performed exclusively in white 
individuals of European ancestry. Exploring these loci in other racial and ethnic groups is 
needed. Second, we used an estimate of whole-body insulin sensitivity derived from post-glucose 
load measures of glucose and insulin, rather than direct measures of insulin sensitivity. The wide 
availability of the ISI provided increased statistical power of the association analyses relative to 
that of other indices which are better correlated with euglycemic measures of insulin sensitivity, 
such as the Matsuda index (26). Assessment of our novel findings in the GENESIS consortium 
suggests that the ISI may be capturing different information on insulin sensitivity than that 
provided by the insulin clamp or the insulin suppression test, or that the power in the GENESIS 
analyses was limited to detect this association. Third, conditional analyses could not be 
performed in Model 3, which would have been the best method of assessing the dependence of 
the signals at BCL2 and FAM19A2. However, the LD for each variant with other known glucose 
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 and insulin loci in the region was low, and the nominally significant associations of the BCL2 
and FAM19A2 variants with ISI were stable after conditioning in Model 2, suggesting that 
analyses in Model 3 would have probably confirmed secondary loci. Fourth, given our desire for 
early dissemination of these results, no experimental attempts at determining the causal gene and 
mechanisms of action in our novel candidate insulin sensitivity loci were performed here.  
 
In conclusion, we identified two novel candidate insulin sensitivity loci through a GWAS of the 
modified Stumvoll Insulin Sensitivity Index. Our results demonstrate that ISI is a robust measure 
of fasting and whole-body measures of insulin sensitivity and suggest that genetic variation in 
the FAM19A2 and BCL2 loci influence insulin sensitivity. While further functional work is 
needed to clarify the causal genes and mechanisms of action of these loci, our work as well as 
prior literature provides support for the role of genes in these loci having an effect on human 
glycemic metabolism.
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Table 1. Cohort and Participant Demographics 
 
Cohort N Female 
(%) 
Age 
(years) 
BMI 
(kg/m
2
) 
Fasting 
Glucose 
(mmol/l ) 
Fasting 
Insulin 
(pmol/l ) 
Stumvoll ISI 
(µmol*pmol/kg*min*l) 
Discovery 
FHS 2602 54 54.0 ± 9.9 26.8 ± 4.5 5.2 ± 0.5 28.6 ± 9.9 0.111 ± 0.012 
Sorbs 802 60 46.3 ± 15.9 26.5 ± 6.4 5.5 ± 1.2 40.7 ± 26.5 0.105 ± 0.023 
FUSION 462 63  66.5 ± 6.7 27.6 ± 4.2 5.1 ± 0.5 68.5 ± 36.0 0.087 ± 0.023 
CHS 2761 62 72.3 ± 5.3 26.0 ± 4.3 5.5 ± 0.5 93.3 ± 47.8 0.059 ± 0.038 
LURIC 962 24 61.9 ± 27.1 27.1 ± 3.8 5.5 ± 0.6 61.6 ± 49.9 0.065 ± 0.038 
ULSAM 962 0 71.0 ± 0.6  26.0 ± 3.2  5.4 ± 0.6 73.0 ± 40.1 0.074 ± 0.031 
METSIM 7388 0 57.0 ± 6.96 26.8 ± 3.8 5.7 ± 0.5   49.8 ± 35.3   0.093  ±0.030 
Replication 
EUGENE2 885 56 39.4 ± 9.2 26.5 ± 4.8 5.1 ± 0.5 49.0 ± 34.9 0.091 ± 0.028 
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 Amish Studies 334 61 45 ± 12.7 27.4 ± 4.7 4.9 ± 0.5 63.4  ± 26.0 0.09  ± 0.02 
RISC 921 56 44 ± 8.37 25.5 ± 4.0 5.1 ± 0.6 34.4 ± 18.7 0.106 ± 0.018 
Tuebingen 2470 65 40.2 ± 13.2 30.9 ± 9.6 5.2 ± 0.6 83.4 ± 72.2 0.070 ± 0.049 
Inter99 5318 51 45.9 ± 7.9 26.1 ± 4.4 5.5 ± 0.5 41.1 ± 26.3 0.101 ± 0.021 
Segovia 420 53 52.1 ± 11.4 26.7 ± 3.8 4.5 ± 0.6 71.2 ± 39.7 0.087 ± 0.025 
Pizarra 640 66 43.6 ± 13.0 27.8 ± 4.9 5.4 ± 0.7 46.6 ± 34.2 0.101 ± 0.023 
Botnia Study 1235 52 58.3 ± 10.2 27.1 ± 3.9 5.4 ± 0.5 44.7 ± 28.7 0.099 ± 0.020 
1936 Birth Cohort 576 54 60.5 ± 0.5 26.5 ± 4.0 5.2 ± 0.5 42.5 ± 23.7 0.098 ± 0.022 
Ely Study 1442 54 61.1 ± 9.2 27.3 ± 4.8 5.00 ± 0.56 57.1 ± 35.7 0.088 ± 0.031 
Continuous results are shown as mean ± standard deviation. FHS: Framingham Heart Study; FUSION: Finland-United States 
Investigation of NIDDM; CHS: Cardiovascular Health Study; LURIC: Ludwigshafen Risk and Cardiovascular Heath; ULSAM: The 
Uppsala Longitudinal Study of Adult Men; METSIM: Metabolic Syndrome in Men; EUGENE2: European Network on Functional 
Genomics of Type 2 Diabetes; RISC: Relationship between Insulin Sensitivity and Cardiovascular Risk Study; Tuebingen: Tuebingen 
Family study for type 2 Diabetes; ISI: insulin sensitivity index. Additional information for each cohort can be found in Supplemental 
Table 1.  
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 Table 2. Meta-Analysis Results for Variant Association with Insulin Sensitivity Index 
SNP Chr Locus Allele 
(Eff/Other) 
Freq Model 1 
(β±SE) 
P-value 
Model 2 
(β±SE) 
P-value 
Model 3  
Main (β±SE) 
Int (β±SE) 
Joint P-value 
 
N 
(min,max) 
rs13422522 2 NYAP2 C/G 0.77 -0.04±0.01 
1.6×10
-5
 
-0.06±0.01 
1.2×10
-11
 
0.10±0.06 
-0.01±0.002 
8.9×10
-11
 30057, 30078.3 
rs4078023 16 GP2 T/G 0.98 -0.028±0.04 
0.49 
-0.05±0.04 
0.20 
0.80±0.17 
-0.03±0.01 
3.2×10
-7
 24727, 24742 
rs12372926 15 ARRDC4 T/C 0.41 -0.03±0.01 
0.001 
-0.03±0.01 
1.6×10
-5 
 
0.11±0.05 
-0.005±0.002 
4.2×10
-4
 30073, 30095 
rs16924527 8 TOX A/C 0.02 0.12±0.04 
0.001ǂ 
0.07±0.03 
0.02 
-0.08±0.14 
0.01±0.01 
3.7×10
-6ǂ
 24994, 25005 
rs2828537 21 MRPL39 A/T 0.97 -0.04±0.03 
0.12 
-0.03±0.02 
0.16 
0.42±0.10 
-0.02±0.004 
2.6×10
-5
 29733, 29753.9 
rs3900087 4 ADAMTS3 T/C 0.98 -0.04±0.05 
0.33 
-0.04±0.04 
0.31 
0.74±0.21 
-0.03±0.01 
4.7×10
-4
 22350, 22351 
rs6027072 20 ARHGAP40 A/G 0.03 0.10±0.02 
0.0001 
0.08±0.02 
4.1×10
-4
 
-0.39±0.12 
0.02±0.005 
4.4×10
-9
 28877, 28896 
rs12454712 18 BCL2 T/C 0.58 -0.04±0.01 
0.0003 
-0.05±0.01 
1.9×10
-8
 
0.04±0.05 
-0.003±0.002 
2.7×10
-8
 25973, 26761 
rs10506418 12 FAM19A2 A/G 0.03 0.06±0.03 
0.05 
0.06±0.03 
0.01 
-0.62±0.13 
0.03±0.005 26011, 26024 
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 1.9×10
-8
 
rs1857095 1 ELTD1 T/C 0.98 -0.01±0.03 
0.84 
-0.02±0.03 
0.37 
0.08±0.12 
-0.0003±0.005 
7.9×10
-9ǂ
 26596, 26608.9 
rs11594101 10 NRG3 A/G 0.98 0.02±0.04 
0.57 
-0.002±0.03 
0.94 
0.62±0.14 
-0.02±0.005 
9.5×10
-5
 27885, 27904 
rs12583553 13 FGF9 A/T 0.97 -0.04±0.03 
0.19 
-0.05±0.03 
0.04 
0.55±0.12 
-0.02±0.005 
3.6×10
-9ǂ
 29195, 29215 
rs4548846 16 CDH13 T/C 0.02 0.02±0.04 
0.72 
-0.002±0.04 
0.96 
0.59±0.18 
-0.03±0.01 
1.1×10
-5ǂ
 18401, 18405.99 
rs12522198 5 FAM134B A/G 0.02 -0.03±0.04 
0.48 
0.01±0.04 
0.84 
0.79±0.19 
-0.03±0.01 
1.6×10
-4ǂ
 19798, 20589 
rs10483182 22 ISX A/G 0.01 0.06±0.04 
0.17 
0.03±0.04 
0.39 
-1.16±0.18 
0.05±0.01 
7.8×10
-12ǂ
 20399, 20409 
rs10520638 15 AGBL1 T/C 0.01 0.004±0.05 
0.93 
-0.01±0.04 
0.77 
0.89±0.19 
-0.04±0.01 
1.2×10
-7ǂ
 12369, 12383 
rs6013915 20 PFDN4 A/G 0.03 0.05±0.03 
0.14 
0.06±0.03 
0.05 
-0.84±0.19 
0.04±0.01 
1.5×10
-9ǂ
 23111, 23121.9 
rs9658121 6 PPARD A/G 0.02 -0.01±0.04 
0.80 
0.02±0.04 
0.63 
-0.40±0.15 
0.02±0.01 
7.3×10
-4ǂ
 16973, 16985 
rs10508754 10 KIAA1462 A/G 0.08 -0.03±0.02 
0.08 
-0.05±0.02 
0.01  
0.14±0.09 
-0.01±0.004 
0.07 25146, 25150 
rs11627967 14 NPAS3 T/G 0.016 -0.02±0.05 
0.69 
-0.03±0.04 
0.44 
-0.94±0.21 
0.04±0.01 17593, 17595.98 
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 1.6×10
-7ǂ
 
rs10495667 2 VSNL1 A/G 0.04 0.02±0.02 
0.32 
0.01±0.02 
0.69 
-0.51±0.12 
0.02±0.005 
3.8×10
-5
 27332, 27345.9 
rs13059110 3 TXNDC6 T/G 0.13 -0.05±0.02 
0.0001 
-0.04±0.01 
2.3×10
-4
 
0.03±0.07 
-0.002±0.003 
0.01 26420, 26425 
rs11790816 9 SH3GL2 T/C 0.02 0.01±0.03 
0.63 
0.02±0.03 
0.45 
-0.37±0.14 
0.02±0.01 
0.001
ǂ
 21814, 21833.92 
Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses the combined influence of the 
SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, the 
effect (β), standard error (SE), and P-values for the SNP are shown. For Model 3, the β and standard error (SE) are provided 
for the SNP and the interaction; P-value is provided for the joint influence of the SNP and interaction effect. Effect sizes are 
presented as standard deviation per effect allele. SNP: single nucleotide polymorphism; Chr: chromosome, Eff: effect allele; 
Freq: frequency of the effect allele); 
ǂ
P-value for heterogeneity in the combined analysis of discovery and replication cohorts 
P≤10
-6
. 
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 Figure Legends 
 
Figure 1. A) Correlation of ISI with M-value from insulin clamp and B) fasting insulin in 
ULSAM. Insulin sensitivity was measured within the ULSAM discovery cohort (n=1025) using 
the euglycemic hyperinsulinemic clamp (M-value), the modified Stumvoll ISI, and fasting 
insulin. The ULSAM cohort contains only men and individuals with known diabetes were 
excluded from these analyses. For the comparison of the M-value with ISI, the Pearson 
correlation was 0.69 and the Spearman correlation was 0.71, which are consistent with prior 
published reports. For the comparison of the ISI with fasting insulin, the Pearson correlation was 
-0.45 and the Spearman correlation was -0.49.  
Figure 2. The effect of rs10506418 (FAM19A2) on insulin sensitivity by BMI category. The 
effect of the minor allele (A) at rs10506418 (FAM19A2) on the ISI is shown by body mass index 
(BMI) category. At low BMI (<20kg/m
2
), the effect is negative. At each category of increasing 
BMI above 20 kg/m
2
, the effect is positive and stronger. 
Figure 3. The effect of rs10506418 (BCL2) on insulin sensitivity by BMI category. The effect 
of the major allele (T) at rs10506418 (BCL2) on the ISI is shown by body mass index (BMI) 
category. At each category of increasing BMI, the effect is negative and stronger. 
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Supplemental Table 1: Detailed cohort information
COHORT FHS Sorbs FUSION CHS LURIC
Discovery or Replication Effort Discovery Discovery Discovery Discovery
Ethnicity White
Sorbs (Slavonic 
origin)
European descent White White
Country USA Germany Finland USA Germany
Collection Type Population-based Population-based Case-control Population-based Case-control 
GLUCOSE MEASUREMENTS
Glucose Sample Fasting plasma
75g OGTT 
(fasting, 30 min, 
120 min), serum
Fasting plasma Fasting plasma Fasting plasma
Glucose Collection method Venipuncture
Overnight fast, 
spinning within 1 
hour after 
collection, then 
immediate quick-
freeze on dry ice 
before transport, 
further storage in 
-80°C freezer
Overnight fast 
and plasma 
collected in 
EDTA tubes
Venipuncture Venipuncture
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Glucose Assay Hexokinase
Hexokinase 
method 
(Automated 
analyser 
Modular, Roche 
Diagnostics, 
Mannheim, 
Germany)
Glucose oxidase 
method (Yellow 
Springs 
instruments, 
Yellow Springs, 
OH and 
autoanalyser) and 
hexokinase 
method
Kodak Ektachem 
700 analyzer 
with reagents 
(Eastman Kodak, 
Rochester, NY)
Hexokinase
INSULIN MEASUREMENTS
Insulin Sample
Fasting and 120 
min plasma
75g OGTT 
(fasting, 30 min, 
120 min), serum
Fasting plasma 
fasting and 120 
min plasma
Fasting, 60 min 
and 120 min 
plasma
Insulin Collection method Venipuncture
Overnight fast, 
spinning within 1 
hour after 
collection, then 
immediate quick-
freeze on dry ice 
before transport, 
further storage in 
-80°C freezer
Overnight fast 
and plasma 
collected in 
EDTA tubes
Venipuncture Venipuncture
Insulin Assay
DPC Coat-a-
Count Total IRI
AutoDELFIA 
Insulin assay 
(PerkinElmer 
Life and 
Analytical 
Sciences, Turku, 
Finland)
RIA with dextran 
charcoal 
separation
competitive 
radioimmunoass
y (Diagnostic 
Products Corp., 
Malver, PA)
AIA pack IRI / 
AIA1200
Insulin Assay sensitivity > 8 pmol/L 3.0 pmol / L 
CV=11% low 
conc, 13% high 
conc
5 - 400 mIU/L
SAMPLES
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EXCLUSIONS
Type 1 diabetes, 
type 2 diabetes
Known diabetes, 
FG ≥ 7 mmol/l, 
120min glucose 
≥ 11.1 mmol/l
Diabetes 
ascertained by 
OGTT, medical 
record review or 
GAD Ab 
positivity; 
diabetes 
medication, 
missing 
phenotype or 
covariate
Use of diabetes 
medications or 
fasting glucose 
>= 7mmols
History of 
diabetes, OGTT, 
fasting glucose > 
7mmol
Samples with STUMVOLL 
phenotype (uniform analysis): N 
all (%males/%females)
2602 
(45.77%/54.23%
)
802 
(40.3%/59.7%)
462 (37% / 63%)
2761 (38.2 / 
61.8)
962 
(76.3%/23.7%)
STUMVOLL [Mean (sd)], units
0.0865288 
(0.02316)
0.037981
Age [Mean (sd) males / Mean (sd) 
females], years
53.94 
(9.90)/54.06 
(9.82)
47.6(16.7)/48.1(1
6.1)
69.05(5.36) / 
65.10 (6.96)
72.9 (5.6) / 71.9 
(5.1)
61.24 (9.90) / 
64.03 (9.80)
BMI [Mean (sd) males / Mean (sd) 
females], kg/m2
27.79 
(3.86)/26.05 
(4.90)
27.1(3.95)/26.7(5
.51)
27.24 (4.12) / 
27.84 (4.23)
26.1 (3.4) / 26.0 
(4.8)
27.21 (3.57) / 
26.77 (4.51)
Fasting PLASMA glucose [Mean 
(sd) males / Mean (sd) females], 
mmol/l
5.3542 
(0.4639)/5.1228 
(0.5027)
5.46(1.10)/5.59(1
.20)
5.12 (0.49) / 5.02 
(0.44)
5.6 (0.5) / 5.5 
(0.5)
5.50 (0.58) / 5.34 
(0.56)
Original units for fasting glucose mg/dl mmol/l mg/dl mg/dl mg/dl
Conversion factor for glucose to 
mmol/l
1/18.01 - 0.05551 18-Jan 18-Jan
Fasting insulin [Mean (sd) males / 
Mean (sd) females], pmol/l
30.186 
(10.925)/27.230 
(8.739)
40.51(24.89)/41.
01(28.02)
66.57 (33.82) / 
69.62 (37.25)
94.7 (45.8) / 92.5 
(49.0)
62.61 (52.41) /  
57.68 (40.73)
Original units for fasting insulin pmol/l pmol/l mU/l mIU/L IU/ml
Conversion factor for insulin to 
pmol/l
1 Not applicable 6 6.945 6
GENOTYPING
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Genotyping platform & SNP panel
Affymetrix 500K 
and MIPS 50K
500K Affymetrix 
GeneChip (250K 
Sty and 250K 
Nsp arrays, 
Affymetrix, Inc) 
and Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0
Illumina 
HumanHap300
Illumina 
HumanCNV370-
Duo BeadChip
Affymetrix 6.0
Genotyping centre Affymetrix
Microarray Core 
Facility of the 
Interdisciplinary 
Centre for 
Clinical 
Research, 
University of 
Leipzig, 
Germany and 
ATLAS Biolabs 
GmbH, Berlin, 
Germany
Center for 
Inherited Disease 
Research
General Clinical 
Research 
Center's 
Phenotyping/Gen
otyping 
Laboratory at 
Cedars-Sinai
LURIC Study 
nonprofit LLC, 
c/o Synlab MVZ 
Heidelberg, 
Wasserturmstrass
e 71, D-69214 
Eppelheim
Genotyping calling algorithm BRLMM
BRLMM 
algorithm 
(Affymetrix, Inc) 
for 500K and 
Birdseed 
Algorithm for 
Genome-Wide 
Human SNP 
Array 6.0
Beadstudio
 Illumina 
BeadStudio 
software
Birdseed v2
SAMPLE QC
Call rate [filter detail] 97% > 94% >97.5% >95% >95%
Heterozygosity [filter detail / N 
individuals excluded]
5 SD from mean 
(< 25.758% or > 
29.958%) / 10
None None None None
Ethnic outliers excluded None Ethnic outliers None
African 
American 
excluded
None
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Other exclusions None
duplicates; 
gender 
mismatch; 
known diabetes, 
FG ≥ 7 mmol/l, 
120min glucose 
≥ 11 mmol/l
None
 1908 persons 
were excluded 
from genotyping 
if they had 
prevalent 
cardiovascular 
disease. Other 
samples were 
excluded for sex 
mismatch and 
discordance with 
prior genotyping.
duplicates, sex 
ambiguity
Individuals for analysis 2602 802 462
3291 available 
(2761 with 
phenotype and 
no DM)
962
SNP QC (prior to imputation)
MAF [filter detail / N SNPs 
excluded]
> 1% / 68,953 1% >1% none > 1%
HWE > 10-6 > 10-6 > 10-6 P > 10-5 > 10-6
Call rate ≥95% 95% ≥ 90% <97% ≥95% 
Other None None
NMI or duplicate 
pair 
discrepancies <= 
3 
<=2 duplicate 
errors or 
Mendelian 
inconsistencies 
(for reference 
CEPH trios), 
heterozygote 
frequency = 0, 
SNP not found in 
HapMap.
None
SNP number in QC'd dataset 378163 378513 306791 306655 750437
IMPUTATION STATS
Imputation software MACH
IMPUTE to 
HapMap2 
reference panel
MACH 1 to 
HapMap release 
21 CEU (phase 
I+II) reference 
panel
BIMBAM v0.99 
with reference to 
HapMap CEU 
using release 22, 
build 36 
MACH with 
reference to 
HapMap CEU 
Panel 2
Imputation quality metrics r2hat ≥ 0.3 Proper-info > 0.4 r2hat>0.3
observed/expecte
d variance ratio < 
0.01
r2>0.3 and 
prob>0.9
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Other SNP QC filters applied? MAF ≥ 1%
MAF>1%, 
HWE<10-4
MAF ≥ 1%
dosage variance 
<0.01
DATA ANALYSIS
Number of SNPs in analysis N 
imputed
2436797 2531712 2476731 2257780 1800000
Adjustments
sex, age, agesq, 
PC1-8
sex,age,bmi sex, age
age, sex, study 
site
sex, age, age2
Analysis method
Linear mixed 
effect models, 
generalized 
estimating 
equations 
(interaction)
linear regression Linear regression linear regression linear regression
Software for analysis
LMEKIN, GEE 
(R package)
SNPTEST/QUIC
KTEST
ProbABEL R
PLINK, 
QUICKTEST
REFERENCES
Reference cohort PMID:21559053 16 PMID: 1669507
Reference GWAS PMID:19729412 PMID: 20031568
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Website
http://www.ncbi.
nlm.nih.gov/proj
ects/gap/cgi-
bin/study.cgi?stu
dy_id=phs00000
7.v2.p1
 - 
http://fusion.sph.
umich.edu
http://www.
chs-
nhlbi.org/
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ULSAM METSIM EUGENE2
Amish 
Studies
RISC Tuebingen Inter99
Discovery Discovery Replication Replication Replication Replication Replication
Northern 
European (white, 
Caucasian)
European 
descent
White Europeans
European 
descent
White Europeans White Europeans Europeans
Sweden Finland
Finland, Sweden, 
Denmark, 
Germany
USA
Austria, 
Denmark, 
Finland, France, 
Germany, 
Greece, The 
Netherlands, 
Ireland, Italy, 
Sweden, Spain, 
Switzerland, 
United Kingdom, 
Serbia, 
Montenegro
Germany Denmark
Population-based Population-based Population-based Family-based Population-based
At-risk 
population 
(family history, 
glucose 
intolerance, 
overweight, prior 
gestational 
diabetes)
Population-based
Fasting plasma Fasting plasma Fasting plasma
Fasting fresh 
venous plasma 
with sodium 
floride and 
potassium 
oxolate
Serum, 0, 30, 60, 
90, 120 min 
OGTT
Plasma, 0, 30,  
60, 90, 120 min 
OGTT
Plasma; 0, 30, 
120 min OGTT
Venipuncture Venipuncture Venipuncture
Fasting venous 
blood collected 
into sodium 
floride tubes, 
plasma frozen 
and stored at -
80oC and thawed 
immediately 
before glucose 
measurement.
Venipuncture Venipuncture Venipuncture
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Glucose 
dehydrogenase 
method (Gluc-
DH, Merck, 
Darmstadt, 
Germany)
Enzymatic 
photometric test, 
Glucose 
hexokinase. 
Glucose oxidase 
method (Glucose 
& Lactate 
Analyzer 2300 
Stat Plus, Yellow 
Springs 
Instrument Co., 
Inc, Ohio)
YSI glucose 
analyzer, Yellow 
Springs, OH
Glucose oxidase 
method (Cobas 
Integra, Roche)
YSI 2300 STAT 
Plus Glucose 
Analyzer 
(glucose oxidase 
method, Yellow 
Springs 
Instruments, 
OH/USA)
Glucose oxidase 
method 
Fasting plasma, 
120 min plasma
Fasting plasma
Serum, 0, 30, 60, 
90, 120 min
Fasting venous 
plasma with 
heparin
Serum, 0, 30, 60, 
90, 120 min 
OGTT
Serum, 0, 30, 60, 
90, 120 min 
OGTT
Serum; 0, 30, 
120 min OGTT
Venipuncture Venipuncture Venipuncture
Fasting venous 
blood collected 
into sodium 
heparin tubes, 
centrifuged at 
4oC within 1 
hour, plasma 
frozen and stored 
at -80oC and 
thawed 
immediately 
before insulin 
measurement.
Venipuncture Venipuncture Venipuncture
Immunoreactive 
insulin: 
Enzymatic-
immunological 
assay (Enzymun, 
Boehringer 
Mannheim)
Immunoassay, 
luminometric 
measurement
Microparticle 
enzyme 
immunoassay 
(Abbott 
Laboratories, 
Tokyo, Japan)
Millipore 125 
Iodine Human 
Insulin RA kit
Insulin, 
proinsulin and C-
peptide were 
measured by a 
two-sited, time-
resolved 
fluoroimmunoass
ay (AutoDELFIA 
Insulin kit, 
Wallac Oy, 
Turku, Finland) 
using 
monoclonal 
antibodies
Insulin 
immunochemilu
minometric assay 
(Advia Centaur 
XP, Siemens, 
Germany)
AutoDELFIA 
insulin kit
3.0 pmol / L 2-200 mU / L 3 pmol/l
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Use of diabetes 
medication, 
fasting plasma 
glucose >= 7 
mmol/L
Diabetes 
ascertained by 
OGTT, medical 
record review or 
GAD Ab 
positivity; 
diabetes 
medication, 
missing 
phenotype or 
covariate
Diabetes 
ascertained by 
OGTT, medical 
record review
Diabetes (either 
self-reported or 
registered as 
using anti-
diabetic drugs), 
FG >= 7 mmol/l, 
Lipid disorders 
or diabetes, lipid 
medications, 
pregnancy
Diabetes 
ascertained by 
OGTT, medical 
record review or 
GAD Ab 
positivity; 
diabetes 
medication
Self-reported 
diabetes, treated 
with anti-
diabetic drugs or 
diabetes at 
OGTT
962 (100% 
males)
7388 (100% / 
0%)
885 (44.3%, 
55.7%)
334 (39%.61%)
921 
(44.1%,55.9%)
2470 (35.1% / 
64.9%)
5318 (49/51)
0.074 (0.031)
0.0928042 
(0.0295312)
0.0914756 
(0.0275914)
0.09  ± 0.02 0.106 (0.018) 0.070 (0.049) 0.101 (0.021)
71.0 (0.6) / NA 57.04(6.96) / NA
39.06 (9.27) / 
39.72 (9.11)
45.3 (13.6)/ 44.8 
(12.1)
43.31 (8.56)/ 
44.46 (8.19)
41.5 (14.4) / 39.6 
(12.6)
46.1 (7.8)/45.6 
(7.8)
26.0 (3.2) / NA
26.84 (3.81) / 
NA
27.00 (4.37) / 
26.07 (5.08)
26.3 (3.5) / 28 
(5.2)
26.36 
(3.54)/24.78 
(4.22)
30.2 (9.0) / 31.4 
(9.9)
26.6 (3.9)/25.6 
(4.8)
5.38 (0.56) /NA 5.71 (0.48) /NA
5.29 (0.52) / 4.98 
(0.44)
5 (0.4) / 4.9 (0.5)
5.20 (0.52) / 4.92 
(0.56)
5.24 (0.55) / 5.12 
(0.55)
5.61 (0.49)/5.3 
(0.49)
mmol/L mmol/l mmol/l mg/dl mmol/l mmol/l mmol/L
No None 0.0555 NA None NA
72.97 (40.10) / 
NA
49.76 (35.29) / 
NA
51.95 (37.87) / 
46.70 (32.22)
60.9 (22.9) / 64.9 
(27.7)
36.80 (19.96)/ 
32.5 (17.42)
82.3 (76.2) / 83.9 
(69.9)
43.1 (27.8)/39.1 
(24.7)
mU/L mU/l pmol/l microU/ml pmol/l pmol/l pmol/L
6 6 Not applicable 6 Not applicable Not applicable Not applicable
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Illumina 
Omni2.5+Metab
ochip
Illumina 
HumanOmniExp
ress-12v1
Infinium 
HumanHap 550 
k version 3 chips
illumina 
OmniChip 2.5M, 
Affy 500K, 
Affy6.0, 
Metabochip
Applied 
Biosystems
Sequenom 
MassArray
KASP 
Genotyping
SNP&SEQ 
Technology 
Platform, 
Uppsala
Center for 
Inherited Disease 
Research
The Finnish 
Genome Centre, 
Helsinki, Finland
Univ of 
Maryland 
Division of 
Endocrinology
Kbioscience
Central 
Laboratory of the 
University 
Hospital 
Tuebingen
LGC Genomics
GenomeStudio 
2010.3
GenomeStudio 
version 2011.1
Sequenom 
MassARRAY 
Typer (version 3)
GeneCall, 
BRLLM
ABI Prism 7000 
sequence 
detection system
iPLEX software KlusterCaller
≥ 95% >98% / 0 99.90% >95% >90%  >95% NA
> 3 s.d. None None None None None NA
MDS analysis 
performed
non-Finnish, 
PCA outliers, 
gender 
discordance
None None None None None
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Related 
individuals, 
missing 
phenotype values
unexpected 
duplicates, 
contamination > 
3%, missing 
phenotype, 
diabetics
None mendelian errors None None None
962 7388 885 2872 921 2470 5318
≥1% none None >1% >5%/0
MAF of 
replicated SNPs 
>0.45% / 0
NA
> 10-6 > 10-6 >0.004 0.000001 0.000001/0 >9.4*10
-8 0.001/0
≥99% 
(MAF<5%) or 
≥95% 
(MAF≥5%)
95% >95% >95% >95%  >95% 95%/0
None
triallelicmap_sco
re<30 / 5314
None None None None None
1587454 681789 12 1944974 13 23 20
IMPUTE2
MACH to 1000 
Genomes phase 
1 integrated 
variant release 
(v3) reference 
panel
Not applicable
IMPUTE v2 
using 1000 
Genomes Phase 
3 reference 
panel
MACH2QTL 
using 1000 
Genomes 
reference panel
Not applicable Not applicable
info>0.4 r2hat>0.3 Not applicable
No filtering done 
post-imputation
Not applicable Not applicable Not applicable
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MAF≥1% MAF ≥ 1% Not applicable
No filtering done 
post-imputation
MAF >= 1% 
r2_hat >= 0.3
3178687 9097160 12 (genotyped) 22
24 (13 
genotyped, 11 
imputed)
23 (none 
imputed)
20
Age, PC1, PC2
Age, agesq, 3 
PCs
Age, sex, center, 
family
Age, age2, sex 
Age, sex, centre, 
the first two 
principal 
components
Age and sex age, sex
Linear regression Linear regression
Mixed linear 
model
Mixed model Linear regression Linear regression
Linear mixed 
effect models, 
generalized 
estimating 
equations 
(interaction)
SNPTEST 
v2.4.1/ Quicktest 
v0.95
ProbABEL SPSS v.17 MMAP STATA 10.1 JMP 10.0.0 R
PMID: 16030278
PMID: 19223598
Laakso M. et al.; Diabetologia 2008;51:502-11 
18440328, 
18805900
Jørgensen, T. et 
al.  A 
randomized non-
pharmacological 
intervention 
study for 
prevention of 
ischaemic heart 
disease: Baseline 
results Inter99 
(1). Eur J 
Cardiovasc Prev 
Rehab  10, 377-
386 (2003)
NA
Böhm A. et al.; 
PLoS One 
2012;7(3):e3403
5
Not applicable Not applicable
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http://www2.pub
care.uu.se/ULSA
M/
http://medschool.
umaryland.edu/e
ndocrinology/am
ish.asp
www.inter99.dk
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Segovia Pizarra Botnia Study Ely Study
1936 Birth 
Cohort
Replication Replication Replication Replication Replication
White Europeans White Europeans White Europeans White Europeans
Spain Spain Finland UK Denmark
Population based Population based
At-risk 
population 
(family history of 
T2D)
Population based population-based
Plasma, 0, 120 
min OGTT
Plasma, 0, 120 
min OGTT
Plasma, 0, 30, 
60, 120 min 
OGTT
Fasting fresh 
venous plasma 
with fluoride
Plasma; 0, 30, 
120 min OGTT
Venipuncture Venipuncture Venipuncture
Overnight fasting 
and Plasma 
centrifuged and 
analyzed 
immediately
Venipuncture
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Plasma glucose 
was estimated in 
duplicate by a 
glucose-oxidase 
method adapted 
to analyser
Colorimetric 
glucose-
deshidrogenase 
method
Glucose oxidase 
method 
(Beckman 
Glucose 
Analyzer, 
Beckman 
Instruments, 
Fullerton, CA)
Hexokinase
Glucose oxidase 
method
Serum, 0,  120 
min OGTT
Serum, 0,  120 
min OGTT
Serum 0, 30, 60, 
120 min OGTT
Fasting venous 
plasma with 
heparin
Serum 0, 30, 120 
min OGTT
Venipuncture Venipuncture Venipuncture
Overnight fasting 
and Fasting 
venous blood 
was immediatelly 
centrifuged and 
plasma frozen at -
80C until 
measurement
Venipuncture
Human Insulin 
Specific RIA kit, 
Linco Research 
Inc., St Louis 
MO, USA) 
RIA, Coat-a-
count Insulin, 
DPC
Radioimmunoass
ay (Pharmacia, 
Uppsala, 
Sweden), 
enzyme linked 
immunoassay 
(DAKO 
Diagnostics Ltd, 
Cambridgeshire, 
UK), and 
fluoroimmunome
tric assay 
(AutoDelfia, 
Perkin Elmer 
Finland, Turku, 
Finland)
Immunometric 
assay
ELISA
with a lower 
detection limit of 
2µU/ml. 
3.6microU/mL
Pharmacia: 
CV=5%; DAKO: 
CV=7.5%
Maximum intra-
assay CV of 
6.6%
SAMPLES
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Diabetes 
ascertained by 
OGTT, medical 
record review
Previous diabetes 
with insulin or 
antidiabetic 
drugs treatment 
and subjects 
diagnosed during 
the OGTT, 
and/or FPG ≥7 
mmol/L. 
Institutionalized 
person, pregnant 
women, and 
those persons 
with a severe 
clinical problem 
or psychological 
disorder. 
Fasting glucose 
≥7.0 mmol/l or 
2h glucose ≥11.1 
mmol/l, known 
T2D or GAD Ab 
positivity, 
missing 
phenotype or 
covariate
Known diabetes, 
fasting plasma 
glucose ≥ 7 
mmol/l
Self-reported 
diabetes, treated 
with anti-diabetic 
drugs or diabetes 
at OGTT
420 
(46.8%/53.2%)
640 
(34.1%/65.9%)
1235 (47.9% / 
52.1%)
1442 (46.4 / 
53.6)
576 
(45.7%/54.3%)
0.0873 (0.02549) 0.10066 ( 0.023) 0.0988 (0.0204) 0.0875 (0.0311) 0.098 (0.022)
51.74(11.50)/52.
41(11.39)
44.2 (13.5) / 43.3 
(12.8)
57.6 (10.5) / 59.0 
(10.0)
61.3(9.2) / 
60.8(9.1)
60.6 (0.41)/60.5 
(0.48)
27.0(3.50)/26.4(4
.08)
28.1 (4.2) / 27.7 
(5.2)
27.0 (3.38) / 27.1 
(4.34)
27.3(3.9) / 
27.2(5.4)
27.0 (3.5)/26.1 
(4.3)
4.66(0.49)/4.41(0
.58)
5.5 (0.7) / 5.3 
(0.7)
5.5 (0.53) / 5.4 
(0.47)
5.13(0.55) / 
4.89(0.55)
5.33 (0.52)/5.13 
(0.48)
mg/dl mg/dL mmol/l mmol/l mmol/L
0.05551 0.05551 None NA NA
12.03(6.29)/11.7
2(6.91)
49.5 (36.7) / 44.9 
(32.8)
46.9 (31.3) / 42.7 
(26.0)
60.4(36.7) / 
54.3(34.6)
45.4 (28.6)/40.0 
(18.2)
µU/ml µU/ml mIU/L pmol/l pmol/L
6 6 6.945 Not applicable Not applicable
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Sequenom 
MassArray
TaqMan® Open 
Array® 
Genotyping 
System (Applied 
Biosystems) 
Affymetrix 
500K, some also 
Illumina 
HumanOmni2.5-
4v1_B
Sequenom
Illumina 
CoreExome/Illu
mina HiScan
CEGEN
Sequencing and 
Genotyping 
Platform. 
Hospital Carlos 
Haya
Broad Institute MRC-Epid
The Novo 
Nordisk 
Foundation 
Center for Basic 
Metabolic 
Research, 
University of 
Copenhagen
iPLEX software
TaqMan 
Genotyper 
Software
BRLMM for 
500K and 
Illumina 
GenomeStudio 
v2010.3
Illumina 
GenCall 
>95% >90% 95% >95% 95%
None None None None
Rare alleles 
(MAF<0.05): -
0.4<F<0.4, 
common alleles 
(MAF>0.05): -
0.03<F<0.03 (16 
excluded)
None None None None None
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None None
Genetic 
fingerprint, 
gender check
None None
420 640
1068 with Affy 
500K, 1235 
when 
complemented 
with Omni2.5
1616 656
>1%/0 >1%/0 Monomorphic None No filter
>10
-2
 / 0 >10
-2
 / 0 >10
-6 None > 10-6
>95% >90%
95% 
(Affymetrix) / 
98% (Illumina)
>98% 95%
None None None None None
21 19 9 23 528515
IMPUTATION 
STATS
Not applicable Not applicable
IMPUTE2 using 
1000 Genomes 
Phase 3 reference 
panel
Not applicable
IMPUTE2 using 
1000 Genomes 
reference panel
Not applicable Not applicable INFO > 0.4 Not applicable
inputeExtract.IN
FO
Page 67 of 104 Diabetes
Not applicable Not applicable Not applicable Not applicable Not applicable
DATA 
ANALYSIS
21(none 
imputed)
19 (none 
imputed)
47 (9 genotyped, 
38 imputed)
23 14
age and sex age and sex
age, sex, centre; 
individuals 
clustered in 
families
age sex, 
with/without 
BMI
age, sex
linear regression linear regression Linear regression linear regression
Linear mixed 
effect models, 
generalized 
estimating 
equations 
(interaction)
SPSS 15.0 R and SPSS 17.0 STATA 13.1 Stata v13.0 R
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Supplemental Table 2. Association of known fasting insulin loci with fasting insulin and ISI in discovery cohorts 
SNP Locus Eff Allele Effect SE P -value N
rs1421085 FTO C 0.02 0.003 1.9 × 10
−15
104062
rs983309 PPP1R3B T 0.03 0.004 3.8 × 10
−14
103030
rs9884482 TET2 C 0.02 0.002 1.4 × 10
−11
108420
rs7903146 TCF7L2 C 0.02 0.003 6.1 × 10
−11
103037
rs10195252 GRB14 T 0.02 0.003 4.9 × 10
−10
99126
rs1167800 HIP1 A 0.02 0.003 2.6 × 10
−9
91416
rs2820436 LYPLAL1 C 0.02 0.003 4.4 × 10
−9
104044
rs2745353 RSPO3 T 0.01 0.002 5.5 × 10
−9
104075
rs731839 PEPD G 0.02 0.003 1.7 × 10
−8
104636
rs4865796 ARL15 A 0.02 0.003 2.1 × 10
−8
100001
rs2972143 IRS1 G 0.01 0.003 3.2 × 10
−8
99566
rs1530559 YSK4 A 0.02 0.003 3.4 × 10
−8
107281
rs2943645 IRS1 T 0.02 0.002 2.3 × 10
−19
99023
SNP Locus Eff Allele Effect SE P -value N
rs10195252 GRB14 T 0.02 0.002 1.3 × 10
−16
98997
rs2126259 PPP1R3B T 0.02 0.003 3.3 × 10
−13
99021
rs4865796 ARL15 A 0.02 0.002 2.2 × 10
−12
98314
rs17036328 PPARG T 0.02 0.003 3.6 × 10
−12
98984
rs731839 PEPD G 0.02 0.002 5.1 × 10
−12
103252
rs974801 TET2 G 0.01 0.002 3.3 × 10
−11
103489
rs459193 ANKRD55-MAP3K1 G 0.02 0.002 1.1 × 10
−10
103378
rs6822892 PDGFC A 0.01 0.002 2.6 × 10
−10
103432
rs4846565 LYPLAL1 G 0.01 0.002 1.8 × 10
−9
99014
rs3822072 FAM13A A 0.01 0.002 1.8 × 10
−8
99977
rs6912327 UHRF1BP1 T 0.02 0.003 2.3 × 10
−8
80010
rs13081389 PPARG A 0.03 0.01 1.6 × 10
-6
52379
rs7578326 IRS1 A 0.02 0.003 2.7 × 10
-11
52379
rs780094 GCKR C 0.02 0.003 3.4 x 10
-12
52379
Published Reports for FI (without BMI 
adjustment)
Published Reports for FI  (with BMI adjustment)
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rs972283 KLF14 G 0.01 0.003 4.4 × 10
-6
52379
SNP Effect SNP SE  P -value N
Int Effect Int SE
-0.06 0.02 4.3 × 10
−20
83116
0.003 0.001
0.02 0.02 2.5 × 10
−14
82318
-0.001 0.001
-0.03 0.03 1.7 × 10
−10
82905
0.00 0.001
0.004 0.02 5.3 × 10
−9
82075
-0.020 0.003
-0.02 0.02 3.7 × 10
−8
82572
0.01 0.003
0.01 0.02 2.0 × 10
−8
81598
2.00×10
-4
0.001
SNP Locus Eff Allele
C
rs7607980 COBLL1- GRB14 T
rs2943634 IRS1 C
Published Reports for FI (Model 3) 
Association of known fasting insulin (FI) variants were tested for association with fasting insulin and the modified insulin sensitivity index (ISI) in different cohorts and in models without adjustment for body mass index (BMI), with adjustment for BMI, and in Model 3 
(test of the combined influence of the genotype effect adjusted for BMI and the interaction effect between the genotype and BMI).  Associations of known FI variants with fasting insulin are reported from published literature (Nat Genet 2012; 44:991-1005 [without BMI 
adjustment], Nat Genet 2012; 44:991-1005 and Diabetes 2014; 63:2158-2171 [with BMI adjustment], and Nat Genet 2012; 44:659-669 [Model 3]) and in the full discovery cohort of the current work (ISI Full Cohort). To compare the association of known FI variants in a 
comparable cohort, associations with FI and ISI were performed in a subset of the full discovery cohort (FHS, Sorbs, FUSION, and, for analyses without BMI adjustment, CHS). Effect sizes are presented as standard deviation per effect allele.  SNP: single nucleotide 
polymorphism; Int: interaction; SE: standard error. 
rs4646949 UHRF1BP1 T
rs2785980 LYPLAL1 T
rs4841132 PPP1R3B A
rs4691380 PDGFC
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Supplemental Table 2. Association of known fasting insulin loci with fasting insulin and ISI in discovery cohorts 
Effect SE P -value N Effect SE P -value
-0.02 0.11 0.12 16753 0.02 0.01 0.02
0.01 0.02 0.55 16753 0.02 0.01 0.04
-0.004 0.01 0.75 16752 0.003 0.01 0.61
-0.02 0.01 0.23 16753 0.01 0.01 0.24
-0.01 0.02 0.49 16752 0.01 0.01 0.07
-0.03 0.02 0.004 16752 0.03 0.01 0.003
-0.03 0.01 0.02 16753 0.02 0.01 0.02
-0.01 0.01 0.22 16753 0.004 0.01 0.51
-0.01 0.02 0.37 13991 0.01 0.01 0.14
-0.04 0.01 0.003 16753 0.01 0.01 0.37
-0.04 0.01 2.00×10
-4
16753 0.01 0.01 0.09
-0.01 0.01 0.30 16753 0.02 0.01 0.02
-0.04 0.01 2.00×10
-4
16753 0.01 0.01 0.11
Effect SE P -value N Effect SE P -value
-0.03 0.01 0.01 16734 0.02 0.01 0.01
0.03 0.02 0.02 16735 0.01 0.01 0.24
-0.04 0.01 1.00×10
-4
16735 0.01 0.01 0.08
-0.07 0.01 1.00×10
-6
16725 0.03 0.01 0.003
-0.02 0.01 0.09 13980 0.02 0.01 0.01
-0.01 0.01 0.23 16735 -0.003 0.01 0.65
-0.04 0.01 3.00×10
-4
16734 0.03 0.01 5.92×10
-5
-0.04 0.01 7.00×10
-5
16735 0.02 0.01 0.002
-0.003 0.01 0.79 16735 0.02 0.01 0.002
-0.003 0.01 0.81 16735 0.004 0.01 0.49
-0.02 0.01 0.08 16734 0.02 0.01 0.01
-0.08 0.02 3.00×10
-5
16735 0.04 0.01 0.00
-0.06 0.01 6.80×10
-9
16735 0.02 0.01 0.00
0.00 0.01 0.70 16725 0.02 0.01 0.00
ISI Full Discovery Cohort (without BMI adjustment)
FI in FHS, Sorbs, FUSION, CHS (without BMI 
adjustment)
ISI Full Discovery Cohort (with BMI adjustment) FI in FHS, Sorbs, FUSION (with BMI adjustment)
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-0.02 0.01 0.07 16735 0.01 0.01 0.18
SNP Effect SNP SE P -value N SNP Effect SNP SE  P -value
Int Effect Int SE Int Effect Int SE
-0.002 0.12 0.002 16685 -0.12 0.05 6.18×10
-5
-0.002 0.004 0.01 0.002
0.08 0.08 5.15×10
-9
16729 -0.02 0.03 1.91×10
-4
-0.078 0.005 0.002 0.001
0.06 0.12 0.13 16735 -0.13 0.06 0.03
0.118 -0.001 0.01 0.002
0.08 0.08 0.001 16735 -0.01 0.04 0.002
-0.078 0.004 0.001 0.001
0.04 0.08 0.25 16726 -0.05 0.04 6.15×10
-5
0.084 -0.002 0.003 0.001
0.01 0.08 0.99 16735 0.03 0.03 0.01
0.081 0.000 -3.72×10
-4
0.001
ISI Full Discovery Cohort (Model 3) FI in FHS, Sorbs, FUSION (Model 3)
Association of known fasting insulin (FI) variants were tested for association with fasting insulin and the modified insulin sensitivity index (ISI) in different cohorts and in models without adjustment for body mass index (BMI), with adjustment for BMI, and in Model 3 
(test of the combined influence of the genotype effect adjusted for BMI and the interaction effect between the genotype and BMI).  Associations of known FI variants with fasting insulin are reported from published literature (Nat Genet 2012; 44:991-1005 [without BMI 
adjustment], Nat Genet 2012; 44:991-1005 and Diabetes 2014; 63:2158-2171 [with BMI adjustment], and Nat Genet 2012; 44:659-669 [Model 3]) and in the full discovery cohort of the current work (ISI Full Cohort). To compare the association of known FI variants in a 
comparable cohort, associations with FI and ISI were performed in a subset of the full discovery cohort (FHS, Sorbs, FUSION, and, for analyses without BMI adjustment, CHS). Effect sizes are presented as standard deviation per effect allele.  SNP: single nucleotide 
Page 73 of 104 Diabetes
N Effect SE P -value N
8991 -0.02 0.02 0.32 6627
9584 0.01 0.03 0.65 6627
9223 -0.04 0.02 0.04 6525
9584 0.01 0.02 0.45 6627
9584 -0.01 0.02 0.50 6627
8810 -0.04 0.02 0.05 5825
9312 -0.01 0.02 0.44 6627
9220 0.02 0.02 0.25 6627
9239 -0.01 0.02 0.61 6627
9290 -0.03 0.02 0.08 6627
9584 -0.03 0.02 0.05 6627
8906 -0.01 0.02 0.68 6627
9584 -0.04 0.02 0.04 6627
N Effect SE P -value N
7851 -0.02 0.02 0.47 3858
7851 0.02 0.03 0.55 3858
7851 -0.05 0.02 0.04 3858
7807 -0.09 0.03 0.005 3848
7851 -0.03 0.02 0.23 3858
7851 -0.03 0.02 0.17 3858
7851 -0.06 0.02 0.02 3858
7851 -0.06 0.02 0.01 3858
7850 -0.02 0.02 0.27 3858
7851 0.02 0.02 0.23 3858
7851 -0.03 0.03 0.19 3858
7851 -0.10 0.04 0.02 3858
7851 -0.03 0.02 0.20 3858
7836 0.01 0.02 0.59 3848
FI in FHS, Sorbs, FUSION, CHS (without BMI ISI in FHS, Sorbs, FUSION, CHS (without BMI 
adjustment)
FI in FHS, Sorbs, FUSION (with BMI adjustment)
ISI in FHS, Sorbs, FUSION (with BMI 
adjustment)
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7851 -0.06 0.02 0.004 3858
N SNP Effect SNP SE P -value N
Int Effect Int SE
10589 0.04 0.15 0.01 6561
-0.004 0.01
10650 0.15 0.11 0.04 6605
-0.01 0.004
10673 0.26 0.18 0.07 6611
-0.01 0.01
10673 0.07 0.10 0.01 6611
-0.005 0.004
10645 0.06 0.11 0.07 6602
-0.004 0.004
10673 0.03 0.11 0.87 6611
-0.002 0.004
FI in FHS, Sorbs, FUSION (Model 3) ISI in FHS, Sorbs, FUSION (Model 3)
Association of known fasting insulin (FI) variants were tested for association with fasting insulin and the modified insulin sensitivity index (ISI) in different cohorts and in models without adjustment for body mass index (BMI), with adjustment for BMI, and in Model 3 
(test of the combined influence of the genotype effect adjusted for BMI and the interaction effect between the genotype and BMI).  Associations of known FI variants with fasting insulin are reported from published literature (Nat Genet 2012; 44:991-1005 [without BMI 
adjustment], Nat Genet 2012; 44:991-1005 and Diabetes 2014; 63:2158-2171 [with BMI adjustment], and Nat Genet 2012; 44:659-669 [Model 3]) and in the full discovery cohort of the current work (ISI Full Cohort). To compare the association of known FI variants in a 
comparable cohort, associations with FI and ISI were performed in a subset of the full discovery cohort (FHS, Sorbs, FUSION, and, for analyses without BMI adjustment, CHS). Effect sizes are presented as standard deviation per effect allele.  SNP: single nucleotide 
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Supplemental Table 3. Results of Discovery, Replication, and Meta-Analysis for Variant Association with Insulin Sensitivity Index
SNP Locus Discovery
Effect (Beta) SE P -value Het P- value
rs13422522 NYAP2
1 -0.05 0.02 0.003 0.16
2 -0.07 0.01 4.29×10
-8 0.15
3 SNP 0.13 0.09 1.86×10
-7 0.43
Interaction -0.01 0.003
rs4078023 GP2
1 -0.07 0.05 0.14 0.17
2 -0.09 0.04 0.04 0.17
3 SNP 1.31 0.23 3.41×10
-10 0.01
Interaction -0.05 0.01
rs12372926 ARRDC4
1 -0.05 0.01 2.27×10
-5
0.01
2 -0.05 0.01 2.18×10
-7
0.02
3 SNP 0.20 0.08 9.71×10
-7 0.06
Interaction -0.01 0.003
rs16924527 TOX
1 0.14 0.05 0.01 0.06
2 0.11 0.05 0.02 0.04
3 SNP -0.80 0.23 7.6×10
-10 0.00
Interaction 0.04 0.01
rs2828537 MRPL39
1 -0.07 0.04 0.06 0.57
2 -0.06 0.03 0.06 0.41
3 SNP 1.08 0.17 1.45×10
-10 0.20
Interaction -0.04 0.01
rs3900087
1 -0.14 0.08 0.10 0.48
2 -0.12 0.07 0.09 0.86
3 SNP 2.29 0.38 9.49×10
-10 0.60
Model
ADAMTS3
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Interaction -0.09 0.01
rs6027072 ARHGAP40
1 0.14 0.03 3.73×10
-5
0.95
2 0.12 0.03 4.3×10
-5
0.97
3 SNP -0.48 0.18 5.7×10
-9 0.37
Interaction 0.02 0.01
rs12454712 BCL2
1 -0.05 0.01 0.0004 0.73
2 -0.07 0.01 1.39×10
-7
0.69
3 SNP 0.12 0.10 5.39×10
-7 0.95
Interaction -0.01 0.004
rs10506418 FAM19A2
1 0.11 0.04 0.01 0.16
2 0.14 0.04 0.001 0.19
3 SNP -0.80 0.25 2.09×10
-8 0.11
Interaction 0.04 0.01
rs1857095 ELTD1
1 0.02 0.05 0.69 0.48
2 0.01 0.04 0.91 0.20
3 SNP 0.88 0.25 5.4×10
-16 0.06
Interaction -0.03 0.01
rs11594101 NRG3
1 0.04 0.05 0.41 0.61
2 0.00 0.04 0.98 0.71
3 SNP 1.61 0.25 8.38×10
-10 0.09
Interaction -0.06 0.01
rs12583553 FGF9
1 -0.05 0.04 0.18 0.04
2 -0.06 0.03 0.08 0.10
3 SNP 1.02 0.19 1.41×10
-10 4.39×10
-5
Interaction -0.04 0.01
rs4548846 CDH13
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1 0.04 0.06 0.46 0.07
2 0.04 0.05 0.46 0.22
3 SNP 1.56 0.28 1.53×10
-9 3.90×10
-15
Interaction -0.06 0.01
rs12522198 FAM134B
1 -0.04 0.05 0.38 0.56
2 -0.04 0.04 0.37 0.61
3 SNP 1.80 0.28 1.18×10
-10 6.13×10
-6
Interaction -0.07 0.01
rs10483182 ISX
1 0.06 0.05 0.27 0.23
2 0.01 0.05 0.78 0.31
3 SNP -1.98 0.26 7.32×10
-15 1.4×10
-5
Interaction 0.08 0.01
rs10520638 AGBL1
1 -0.001 0.08 0.99 0.03
2 -0.004 0.07 0.95 0.03
3 SNP 2.01 0.33 8.27×10
-14 1.96×10
-6
Interaction -0.08 0.01
rs6013915 PFDN4
1 0.05 0.05 0.35 0.06
2 0.07 0.04 0.13 0.15
3 SNP -0.96 0.27 6.32×10
-8 2.6×10
-5
Interaction 0.04 0.01
rs9658121 PPARD
1 0.09 0.07 0.25 0.003
2 0.13 0.07 0.06 0.003
3 SNP -0.49 0.33 1.54×10
-7 3.06×10
-6
Interaction 0.03 0.01
rs10508754 KIAA1462
1 -0.14 0.03 1.07×10
-5
0.30
2 -0.15 0.03 2.55×10
-7
0.10
3 SNP 0.19 0.22 2.64×10
-5 0.14
Page 78 of 104Diabetes
Interaction -0.01 0.01
rs11627967 NPAS3
1 -0.04 0.06 0.53 0.10
2 -0.04 0.05 0.46 0.08
3 SNP -1.46 0.28 1.01×10
-9 1.42×10
-13
Interaction 0.06 0.01
rs10495667 VSNL1
1 0.09 0.04 0.01 0.50
2 0.09 0.03 0.01 0.71
3 SNP -0.90 0.18 3.83×10
-9 0.12
Interaction 0.04 0.01
rs13059110 TXNDC6
1 -0.10 0.02 1.6×10
-6
0.18
2 -0.09 0.02 3.69×10
-7
0.12
3 SNP 0.20 0.14 8.84×10
-5 0.08
Interaction -0.01 0.01
rs11790816 SH3GL2
1 0.03 0.06 0.59 0.06
2 0.03 0.05 0.52 0.15
3 SNP -1.38 0.26 3.56×10
-9 2.06×10
-4
Interaction 0.06 0.01
Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses the combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, 
the effect, SE, and P -values for the SNP are shown. For Model 3, the effect (beta) and SE are provided for the SNP and the interaction; 
deviation per effect allele. SNP: single nucleotide polymorphism; Het P -value: heterogeneity P -value for the model. 
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Supplemental Table 3. Results of Discovery, Replication, and Meta-Analysis for Variant Association with Insulin Sensitivity Index
Replication
N Effect (Beta) SE P -value Het P- value N Effect (Beta)
16752.3 -0.05 0.02 0.00 0.19 13326 -0.04
16735 -0.05 0.01 5.53×10
-5
0.51 13322 -0.06
16735 0.07 0.07 3.00×10
-4
0.29 13322 0.10
0.00 0.003 -0.01
13185 0.07 0.07 0.36 0.45 11557 -0.03
13171 0.04 0.06 0.51 0.06 11556 -0.05
13171 0.11 0.25 0.79 0.13 11556 0.80
-0.003 0.01 -0.03
16753 -0.0004 0.01 0.98 0.27 13342 -0.03
16735 -0.01 0.01 0.54 0.07 13338 -0.03
16735 0.07 0.06 0.57 0.05 13338 0.11
-0.002 0.002 -0.005
13523 0.10 0.05 0.05 1.48×10
-7
11482 0.12
13514 0.04 0.04 0.40 0.30 11480 0.07
13514 0.38 0.17 0.05 8.07×10
-6
11480 -0.08
-0.01 0.01 0.01
16752.9 -0.01 0.04 0.74 0.05 13001 -0.04
16735 -0.004 0.03 0.90 0.29 12998 -0.03
16735 0.02 0.13 0.92 0.30 12998 0.42
-0.001 0.005 -0.02
10784 -0.003 0.05 0.96 0.46 11567 -0.04
10784 -0.01 0.05 0.91 0.42 11566 -0.04
10784 -0.02 0.25 0.79 0.03 11566 0.74
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-8.87×10
-5
0.01 -0.03
16753 0.04 0.04 0.28 0.21 12143 0.10
16735 0.02 0.03 0.53 0.09 12142 0.08
16735 -0.30 0.16 0.07 0.08 12142 -0.39
0.01 0.01 0.02
13190 -0.02 0.01 0.11 0.62 12783 -0.04
13982 -0.03 0.01 0.01 0.26 12779 -0.05
13982 0.02 0.07 0.01 0.06 12779 0.04
-0.002 0.003 -0.003
13992 0.01 0.04 0.74 0.83 12032 0.06
13982 0.01 0.04 0.73 0.61 12029 0.06
13982 -0.51 0.15 0.004 0.26 12029 -0.62
0.02 0.01 0.03
13991.9 -0.02 0.04 0.57 0.03 12617 -0.01
13982 -0.04 0.03 0.23 0.08 12614 -0.02
13982 -0.17 0.14 0.04 0.01 12614 0.08
0.004 0.01 -2.82×10
-4
16753 -0.01 0.05 0.91 0.91 11151 0.02
16735 -0.01 0.05 0.90 0.80 11150 0.00
16735 0.08 0.18 0.83 0.92 11150 0.62
-0.004 0.01 -0.02
16753 -0.02 0.04 0.69 0.81 12462 -0.04
16735 -0.04 0.04 0.31 0.74 12460 -0.05
16735 0.19 0.16 0.16 0.07 12460 0.55
-0.01 0.01 -0.02
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8811.99 -0.03 0.08 0.75 0.31 9594 0.02
8810 -0.07 0.07 0.29 0.63 9591 -0.002
8810 -0.43 0.29 0.05 0.19 9591 0.59
0.01 0.01 -0.03
13190 0.01 0.08 0.93 0.70 6608 -0.03
13982 0.11 0.06 0.09 0.51 6607 0.01
13982 -0.41 0.28 0.14 3.37×10
-15
6607 0.79
0.02 0.01 -0.03
13992 0.06 0.08 0.43 0.76 6417 0.06
13982 0.07 0.06 0.29 0.75 6417 0.03
13982 -0.27 0.26 0.21 0.87 6417 -1.16
0.01 0.01 0.05
7601 0.12 0.09 0.17 0.77 4782 0.004
7587 0.05 0.07 0.47 0.35 4782 -0.01
7587 0.38 0.26 0.22 0.10 4782 0.89
-0.01 0.01 -0.04
13991.9 0.05 0.05 0.25  3.30×10
-4
9130 0.05
13982 0.05 0.04 0.23 0.01 9129 0.06
13982 -0.56 0.29 0.04 0.004 9129 -0.84
0.02 0.01 0.04
6142 -0.05 0.05 0.27 0.97 10843 -0.01
6132 -0.03 0.04 0.51 0.98 10841 0.02
6132 -0.33 0.16 0.10 0.93 10841 -0.40
0.01 0.01 0.02
12363 0.03 0.02 0.26 0.83 12787 -0.03
12363 0.01 0.02 0.72 0.72 12783 -0.05
12363 0.17 0.10 0.17 0.55 12783 0.14
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-0.01 0.004 -0.01
8811.98 0.02 0.09 0.79 0.60 8784 -0.02
8810 -0.02 0.07 0.79 0.57 8783 -0.03
8810 -0.10 0.32 0.95 0.38 8783 -0.94
0.003 0.01 0.04
13991.9 -0.01 0.03 0.73 0.74 13354 0.02
13982 -0.03 0.03 0.34 0.97 13350 0.01
13982 -0.13 0.17 0.51 0.21 13350 -0.51
0.004 0.01 0.02
13984 -0.01 0.02 0.52 0.13 12441 -0.05
13982 -0.01 0.02 0.77 0.65 12438 -0.04
13982 -0.04 0.09 0.79 0.06 12438 0.03
0.001 0.003 -0.002
9364.92 -0.01 0.04 0.84 0.39 12469 0.01
9347 0.01 0.04 0.89 0.90 12467 0.02
9347 0.13 0.17 0.45 0.42 12467 -0.37
-0.004 0.01 0.02
Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses the combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, 
-values for the SNP are shown. For Model 3, the effect (beta) and SE are provided for the SNP and the interaction; P -value is provided for the joint influence of the SNP and interaction effect. Effect sizes are presented as standard 
-value for the model. 
Page 83 of 104 Diabetes
Combined Meta-Analysis
SE P -value Het P- value N
0.01 1.64×10
-5
0.14 30078.3
0.01 1.20×10
-11
0.26 30057
0.06 8.87×10
-11
0.29 30057
0.002
0.04 0.49 0.18 24742
0.04 0.20 0.03 24727
0.17 3.17×10
-7
4.23×10
-5
24727
0.01
0.01 0.001 0.002 30095
0.01 1.16×10
-5
4.35×10
-4
30073
0.05 4.20×10
-4
0.001 30073
0.002
0.04 0.001 2.57×10
-7
25005
0.03 0.02 0.05 24994
0.14 3.72×10
-6
2.29×10
-15
24994
0.01
0.03 0.12 0.12 29753.9
0.02 0.16 0.28 29733
0.10 2.60×10
-5
3.19×10
-4
29733
0.004
0.05 0.33 0.42 22351
0.04 0.31 0.52 22350
0.21 4.66×10
-4
1.75×10
-5
22350
Page 84 of 104Diabetes
0.01
0.02 9.43×10
-5
0.41 28896
0.02 4.05×10
-4
0.18 28877
0.12 4.36×10
-9
0.02 28877
0.005
0.01 2.80×10
-4
0.64 25973
0.01 1.87×10
-8
0.21 26761
0.05 2.67×10
-8
0.19 26761
0.002
0.03 0.05 0.30 26024
0.03 0.01 0.10 26011
0.13 1.92×10
-8
0.01 26011
0.005
0.03 0.84 0.08 26608.9
0.03 0.37 0.08 26596
0.12 7.91×10
-9
7.83×10
-10
26596
0.005
0.04 0.57 0.87 27904
0.03 0.94 0.90 27885
0.14 9.46×10
-5
0.001 27885
0.01
0.03 0.19 0.22 29215
0.03 0.04 0.35 29195
0.12 3.60×10
-9
6.92×10
-8
29195
0.005
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0.04 0.72 0.35 18405.99
0.04 0.96 0.65 18401
0.18 1.12×10
-5
1.21×10
-16
18401
0.01
0.04 0.48 0.79 19798
0.04 0.84 0.38 20589
0.19 1.57×10
-4
8.00×10
-27
20589
0.01
0.04 0.17 0.53 20409
0.04 0.39 0.57 20399
0.18 7.82×10
-12
1.18×10
-7
20399
0.01
0.05 0.93 0.09 12383
0.04 0.77 0.08 12369
0.19 1.21×10
-7
6.78×10
-13
12369
0.01
0.03 0.14 4.64×10
-4
23121.9
0.03 0.05 0.01 23111
0.19 1.52×10
-9
6.03×10
-7
23111
0.01
0.04 0.80 0.02 16985
0.04 0.63 0.02 16973
0.15 0.001 1.65×10
-8
16973
0.01
0.02 0.08 0.01 25150
0.02 0.01 0.001 25146
0.09 0.07 0.004 25146
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0.004
0.05 0.69 0.31 17595.98
0.04 0.44 0.29 17593
0.21 1.55×10
-7
3.90×10
-15
17593
0.01
0.02 0.32 0.37 27345.9
0.02 0.69 0.32 27332
0.12 3.76×10
-5
1.58×10
-4
27332
0.010
0.01 1.10×10
-4
0.01 26425
0.01 2.26×10
-4
0.01 26420
0.07 0.01 0.002 26420
0.003
0.03 0.63 0.15 21833.92
0.03 0.45 0.63 21814
0.14 0.001 2.72×10
-7
21814
0.01
Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses the combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, 
-value is provided for the joint influence of the SNP and interaction effect. Effect sizes are presented as standard 
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Supplemental Table 4. Results of Meta-Analysis for Variant Association with Insulin Sensitivity Index Using Minor Allele Count Filter
SNP Locus
Effect (Beta) SE P -value Het P- value
rs13422522 NYAP2
1 -0.04 0.01 1.64×10
-5
0.14
2 -0.06 0.01 1.20×10
-11
0.26
3 SNP 0.10 0.06 8.87×10
-11
0.29
Interaction -0.01 0.002
rs4078023 GP2
1 -0.02 0.04 0.65 0.34
2 -0.04 0.04 0.30 0.08
3 SNP 0.46 0.18 0.03 0.05
Interaction -0.02 0.01
rs12372926 ARRDC4
1 -0.03 0.01 0.001 0.002
2 -0.03 0.01 1.61×10
-5
4.35×10
-4
3 SNP 0.11 0.05 4.20×10
-4
5.59×10
-4
Interaction -0.005 0.002
rs16924527 TOX
1 0.12 0.04 0.001 8.10×10
-7
2 0.07 0.03 0.02 0.13
3 SNP 0.18 0.14 0.01 9.95×10
-7
Interaction -0.004 0.01
rs2828537 MRPL39
1 -0.04 0.03 0.13 0.10
2 -0.03 0.02 0.17 0.23
3 SNP 0.41 0.10 3.56×10
-5
1.45×10
-4
Interaction -0.02 0.004
rs3900087
1 -0.04 0.05 0.33 0.42
2 -0.04 0.04 0.31 0.52
Model
ADAMTS3
Combined Meta-Analysis using MAC < 20 filter in Discovery 
Cohorts
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3 SNP 0.74 0.21 4.66×10
-4
1.75×10
-5
Interaction -0.03 0.01
rs6027072 ARHGAP40
1 0.10 0.02 9.43×10
-5
0.41
2 0.08 0.02 4.05×10
-4
0.18
3 SNP -0.39 0.12 4.36×10
-9
0.02
Interaction 0.02 0.005
rs12454712 BCL2
1 -0.04 0.01 2.80×10
-4
0.64
2 -0.05 0.01 1.87×10
-8
0.21
3 SNP 0.04 0.05 2.67×10
-8
0.19
Interaction -0.003 0.002
rs10506418 FAM19A2
1 0.05 0.03 0.09 0.54
2 0.06 0.03 0.02 0.20
3 SNP -0.58 0.13 7.96×10
-7
0.07
Interaction 0.02 0.005
rs1857095 ELTD1
1 -0.01 0.03 0.84 0.06
2 -0.02 0.03 0.36 0.05
3 SNP 0.09 0.12 0.09 0.001
Interaction -0.01 0.005
rs11594101 NRG3
1 0.02 0.04 0.57 0.87
2 -0.002 0.03 0.94 0.90
3 SNP 0.62 0.14 9.46×10
-5
0.001
Interaction -0.02 0.01
rs12583553 FGF9
1 -0.04 0.03 0.17 0.69
2 -0.05 0.03 0.04 0.76
3 SNP 0.21 0.13 0.01 0.18
Interaction -0.01 0.01
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rs4548846 CDH13
1 0.02 0.04 0.63 0.49
2 0.002 0.04 0.96 0.75
3 SNP -0.45 0.21 0.08 0.20
Interaction 0.02 0.01
rs12522198 FAM134B
1 -0.03 0.04 0.52 0.74
2 0.01 0.04 0.80 0.32
3 SNP 0.79 0.19 1.66×10
-4
9.26×10
-28
Interaction -0.03 0.01
rs10483182 ISX
1 0.06 0.04 0.16 0.46
2 0.03 0.04 0.39 0.47
3 SNP -0.41 0.21 0.07 0.44
Interaction 0.02 0.01
rs10520638 AGBL1
1 0.01 0.05 0.78 0.13
2 -0.01 0.04 0.88 0.08
3 SNP 0.15 0.21 0.76 0.03
Interaction -0.01 0.01
rs6013915 PFDN4
1 0.05 0.03 0.18 0.001
2 0.05 0.03 0.07 0.02
3 SNP -0.26 0.22 0.03 0.02
Interaction 0.01 0.01
rs9658121 PPARD
1 -0.01 0.04 0.80 0.02
2 0.02 0.04 0.63 0.02
3 SNP -0.40 0.15 0.001 1.65×10
-8
Interaction 0.02 0.01
rs10508754 KIAA1462
1 -0.03 0.02 0.08 0.01
2 -0.05 0.02 0.01 0.001
3 SNP 0.14 0.09 0.07 0.004
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Interaction -0.01 0.004
rs11627967 NPAS3
1 -0.03 0.05 0.54 0.70
2 -0.04 0.04 0.33 0.76
3 SNP 0.30 0.26 0.52 0.28
Interaction -0.01 0.01
rs10495667 VSNL1
1 0.02 0.02 0.32 0.37
2 0.01 0.02 0.69 0.32
3 SNP -0.51 0.12 3.76×10
-5
1.58×10
-4
Interaction 0.02 0.005
rs13059110 TXNDC6
1 -0.05 0.01 1.10×10
-4
0.01
2 -0.04 0.01 2.26×10
-4
0.01
3 SNP 0.03 0.07 0.01 0.002
Interaction -0.002 0.003
rs11790816 SH3GL2
1 0.01 0.03 0.80 0.33
2 0.02 0.03 0.58 0.84
3 SNP -0.06 0.15 0.44 0.21
Interaction 0.003 0.01
In a sensitivity analysis, the combined meta-analyses were repeating removing all SNPs with a minor allele count (MAC) < 20 in the discovery and replication cohorts.  As compared 
to when a minor allele frequency (MAF) < 1% was applied to the discovery cohorts and MAC < 20 was applied to replication cohorts in the combined meta-analysis (as shown in 
Table 2 and Supplemental Table 3 and repeated here for comparison), application of the MAC filter to both the discovery and replication cohorts in the combined meta-analysis 
reduced the heterogeneity of some results in the Model 3 and for the results of the PFDN4  locus association in Model 1. The application of this MAC filter tended to reduce the 
statistical significance of associations with high heterogeneity. It also slightly reduced the statistical significance of the association at the 
markedly reducing the magnitude of effect or affecting heterogeneity. The sample size for the FAM19A2
filter was applied in the discovery cohorts versus when the MAF filter was applied. Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses 
the combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, the effect, SE, and P-values 
for the SNP are shown. For Model 3, the effect (beta) and SE are provided for the SNP and the interaction; P-value is provided for the joint influence of the SNP and interaction 
effect. Effect sizes are presented as standard deviation per effect allele. SNP: single nucleotide polymorphism; Het P-value: heterogeneity P-value for the model.        
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Supplemental Table 4. Results of Meta-Analysis for Variant Association with Insulin Sensitivity Index Using Minor Allele Count Filter
N Effect (Beta) SE P -value Het P- value N
30078.3 -0.04 0.01 1.64×10
-5
0.14 30078.3
30056.3 -0.06 0.01 1.20×10
-11
0.26 30057
30056.3 0.10 0.06 8.87×10
-11
0.29 30057
-0.01 0.002
21844 -0.03 0.04 0.49 0.18 24742
21829 -0.05 0.04 0.20 0.03 24727
21829 0.80 0.17 3.17×10
-7
4.23×10
-5
24727
-0.03 0.01
30095 -0.03 0.01 0.001 0.002 30095
30073 -0.03 0.01 1.16×10
-5
4.35×10
-4
30073
30073 0.11 0.05 4.20×10
-4
0.001 30073
-0.005 0.002
25005 0.12 0.04 0.001 2.57×10
-7
25005
24993 0.07 0.03 0.02 0.05 24994
24993 -0.08 0.14 3.72×10
-6
2.29×10
-15
24994
0.01 0.01
29291.9 -0.04 0.03 0.12 0.12 29753.9
29270.9 -0.03 0.02 0.16 0.28 29733
29270.9 0.42 0.10 2.60×10
-5
3.19×10
-4
29733
-0.02 0.004
21557 -0.04 0.05 0.33 0.42 22351
22350 -0.04 0.04 0.31 0.52 22350
Combined Meta-Analysis using MAC < 20 filter in Discovery Combined Meta-Analysis using MAF <1%  filter in Discovery 
Cohorts (repeated from Table 2 and Supplemental Table 3)
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21557 0.74 0.21 4.66×10
-4
1.75×10
-5
22350
-0.03 0.01
28896 0.10 0.02 9.43×10
-5
0.41 28896
28877 0.08 0.02 4.05×10
-4
0.18 28877
28877 -0.39 0.12 4.36×10
-9
0.02 28877
0.02 0.005
25973 -0.04 0.01 2.80×10
-4
0.64 25973
25961 -0.05 0.01 1.87×10
-8
0.21 26761
25961 0.04 0.05 2.67×10
-8
0.19 26761
-0.003 0.002
25562 0.06 0.03 0.05 0.30 26024
25549 0.06 0.03 0.01 0.10 26011
25549 -0.62 0.13 1.92×10
-8
0.01 26011
0.03 0.005
26146.9 -0.01 0.03 0.84 0.08 26608.9
26133.9 -0.02 0.03 0.37 0.08 26596
26133.9 0.08 0.12 7.91×10
-9
7.83×10
-10
26596
-2.82×10
-4
0.005
27904 0.02 0.04 0.57 0.87 27904
27885 0.00 0.03 0.94 0.90 27885
27885 0.62 0.14 9.46×10
-5
0.001 27885
-0.02 0.01
27951 -0.04 0.03 0.19 0.22 29215
27933 -0.05 0.03 0.04 0.35 29195
27933 0.55 0.12 3.60×10
-9
6.92×10
-8
29195
-0.02 0.005
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23124 0.02 0.04 0.72 0.35 18405.99
23111 -0.002 0.04 0.96 0.65 18401
23111 0.59 0.18 1.12×10
-5
1.21×10
-16
18401
-0.03 0.01
19336 -0.03 0.04 0.48 0.79 19798
20127 0.01 0.04 0.84 0.38 20589
19336 0.79 0.19 1.57×10
-4
8.00×10
-27
20589
-0.03 0.01
19947 0.06 0.04 0.17 0.53 20409
19937 0.03 0.04 0.39 0.57 20399
19937 -1.16 0.18 7.82×10
-12
1.18×10
-7
20399
0.05 0.01
19309 0.004 0.05 0.93 0.09 12383
19295 -0.01 0.04 0.77 0.08 12369
19295 0.89 0.19 1.21×10
-7
6.78×10
-13
12369
-0.04 0.01
22659.9 0.05 0.03 0.14 4.64×10
-4
23121.9
22648.9 0.06 0.03 0.05 0.01 23111
22648.9 -0.84 0.19 1.52×10
-9
6.03×10
-7
23111
0.04 0.01
16985 -0.01 0.04 0.80 0.02 16985
16973 0.02 0.04 0.63 0.02 16973
16973 -0.40 0.15 0.001 1.65×10
-8
16973
0.02 0.01
24359 -0.03 0.02 0.08 0.01 25150
24345 -0.05 0.02 0.01 0.001 25146
24345 0.14 0.09 0.07 0.004 25146
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-0.01 0.004
17134 -0.02 0.05 0.69 0.31 17595.98
17131 -0.03 0.04 0.44 0.29 17593
17131 -0.94 0.21 1.55×10
-7
3.90×10
-15
17593
0.04 0.01
30106.9 0.02 0.02 0.32 0.37 27345.9
30084.9 0.01 0.02 0.69 0.32 27332
30084.9 -0.51 0.12 3.76×10
-5
1.58×10
-4
27332
0.02 0.010
26425 -0.05 0.01 1.10×10
-4
0.01 26425
26412 -0.04 0.01 2.26×10
-4
0.01 26420
26412 0.03 0.07 0.01 0.002 26420
-0.002 0.003
28759.9 0.01 0.03 0.63 0.15 21833.92
28739.9 0.02 0.03 0.45 0.63 21814
28739.9 -0.37 0.14 0.001 2.72×10
-7
21814
0.02 0.01
In a sensitivity analysis, the combined meta-analyses were repeating removing all SNPs with a minor allele count (MAC) < 20 in the discovery and replication cohorts.  As compared 
to when a minor allele frequency (MAF) < 1% was applied to the discovery cohorts and MAC < 20 was applied to replication cohorts in the combined meta-analysis (as shown in 
Table 2 and Supplemental Table 3 and repeated here for comparison), application of the MAC filter to both the discovery and replication cohorts in the combined meta-analysis 
 locus association in Model 1. The application of this MAC filter tended to reduce the 
statistical significance of associations with high heterogeneity. It also slightly reduced the statistical significance of the association at the FAM19A2  locus in Model 3 without 
FAM19A2  locus association in Model 3 was 462 individuals fewer when the MAC 
filter was applied in the discovery cohorts versus when the MAF filter was applied. Model 1 is adjusted for age and sex; Model 2 is adjusted for age, sex, and BMI; Model 3 assesses 
the combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI. For Model 1 and Model 2, the effect, SE, and P-values 
for the SNP are shown. For Model 3, the effect (beta) and SE are provided for the SNP and the interaction; P-value is provided for the joint influence of the SNP and interaction 
effect. Effect sizes are presented as standard deviation per effect allele. SNP: single nucleotide polymorphism; Het P-value: heterogeneity P-value for the model.        
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Supplemental Table 6. In silico  findings for rs12454712 (BCL2 ) and rs10506418 (FAM19A2 )
rs12454712 (BCL2 )Conditioning results at rs12454712 (BCL2 ) on the signal from the obesity locus rs663129 (MC4R ), 
located 3 Mb away (LD r
2
 < 0.0001), did not attenuate the association with the ISI in the discovery 
cohorts of Model 2 (beta = -0.067 ± 0.01, P = 1.4 × 10-7 to beta = -0.067 ± 0.01, P =1.6 × 10-7), and no 
other genome-wide significant findings for glycemic traits are present on chromosome 18. 
The major (T) allele of rs12454712 (BCL2 ) was also associated with a trend toward reduced insulin 
sensitivity as measured by M value from direct measures of insulin sensitivity in the GENESIS 
consortium (beta = -0.0275 ± 0.03, P=0.41, N=2,764). When the variant at BCL2 was tested in the 
same subset of discovery cohorts (FHS, Sorbs, FUSION), the associations with fasting insulin and ISI 
were not significant (for fasting insulin SNP effect = -0.11 ± 0.07, interaction effect 0.004 ± 0.003, 
P=0.25, N=7,819 and for ISI SNP effect = -0.03 ± 0.22, interaction effect -0.001 ± 0.01, P=0.24, 
factor binding (RegulomeDB score 2b = TF binding + any motif + DNAse footprint + DNAse peak). 
Using the UCSC Genome Browser, binding motifs to several transcription factors are evident (MYC, 
phosphatase that mediates dephosphorylation of AKT1, AKT2, and AKT3, which has a role in 
regulation of apopotosis and insulin signaling (www.Uniprot.org). Thus, this locus may play a role in 
rs10506418 (FAM19A2 )
Conditioning the result at rs10506418 (FAM19A2 , chromosome 12) on signals from known glucose 
and insulin loci within 100 Mb did not attenuate the association with the ISI in the discovery cohorts of 
Model 2 (beta = 0.139 ± 0.04, P= 4.50 × 10-4 (unconditioned) to beta = 0.139 ± 0.04, P = 4.57 × 10-4 
when conditioned on rs35767 (IGF1, LD r
2
 = 0.0005), to beta = 0.139 ± 0.04, P= 4.54 × 10-4 when 
When rs10506418 was tested in the same subset of discovery cohorts (FHS, Sorbs, FUSION), the 
associations with fasting insulin and ISI were not significant (for fasting insulin SNP effect = 0.33 ± 
0.13, interaction effect -0.01 ± 0.13, P =0.06, N=7,851 and for ISI SNP effect = -0.17 ± 0.48, 
interaction effect -0.01 ± 0.01, P =0.85, N=3,396). However, for the fasting insulin and ISI analyses, 
acting as regulators of immune and nervous cells primarily in the brain. 
Multiple SNPs within 1 Mb (e.g ., rs17125631) are associated at nominal significance with type 2 
diabetes and fasting insulin, although these are not in LD with our finding at rs10506418. The genomic 
region containing FAM19A2 also contains USP15, a hydrolase that removes ubiquitin from target 
proteins and regulates several pathways, including TGF-beta receptor signaling and NF-kappa-B 
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rs12454712
BMI (kg/m
2
)
Full Cohort
FHS, Sorbs, 
FUSION
Manning et al
FHS, Sorbs, 
FUSION
< 20 -0.02 -0.05 0.01 -0.03
20-24.9 -0.04 -0.06 0.02 0.00
25-29.9 -0.06 -0.06 0.02 0.02
30-34.9 -0.07 -0.07 0.03 0.04
≥35 -0.09 -0.08 0.03 0.06
The association of the T allele rs12454712 (BCL2 ) and the A allele rs10506418 (FAM19A2
(BMI). The effect (beta) is derived from the Model 3 analyses in the full cohort of the current study for ISI (the same data in Figure 2 and Figure 3) and from a published 
dataset for fasting insulin (Nat Genet 2012; 44:659-669). To compare the effects in the same cohorts, the Model 3 associations for ISI and fasting insulin were performed in 
the same subset of discovery cohorts (FHS, Sorbs, FUSION). Effect sizes are presented as standard deviation per effect allele at each strata of BMI. Model 3: test of the 
combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI.
Supplemental Table 3: Association for rs12454712 (BCL2 ) and rs10506418 (FAM19A2 ) with ISI and fasting insulin at different strata of body mass index
ISI Fasting Insulin
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rs10506418
Full Cohort FHS, Sorbs, FUSION Manning et al FHS, Sorbs, FUSION
-0.10 -0.02 0.01 0.10
0.03 0.02 0.00 0.04
0.16 0.06 -0.01 -0.01
0.30 0.09 -0.03 -0.06
0.43 0.13 -0.04 -0.11
FAM19A2 ) with ISI and fasting insulin is shown at different strata of body mass index 
(BMI). The effect (beta) is derived from the Model 3 analyses in the full cohort of the current study for ISI (the same data in Figure 2 and Figure 3) and from a published 
dataset for fasting insulin (Nat Genet 2012; 44:659-669). To compare the effects in the same cohorts, the Model 3 associations for ISI and fasting insulin were performed in 
the same subset of discovery cohorts (FHS, Sorbs, FUSION). Effect sizes are presented as standard deviation per effect allele at each strata of BMI. Model 3: test of the 
combined influence of the SNP effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI.
) with ISI and fasting insulin at different strata of body mass index
ISI Fasting Insulin
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Supplemental Figure 1: QQ plot of association statistics in genome-wide scan for discovery effort (n= 16,753 participants) in 
Model 1 (adjusted for age and sex only). 
). 
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Supplemental Figure 2: QQ plot of association statistics in genome-wide scan for discovery effort (n= 16,735 participants) in 
Model 2 (adjusted for age, sex, and body mass index). 
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Supplemental Figure 3: QQ plot of association statistics in genome-wide scan for discovery effort (n= 16,735) participants in 
Model 3 (adjusted for age and sex and analyzing combined influence of the SNP effect adjusted for body mass index [BMI] 
and the interaction effect between genotype and BMI on ISI). 
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Supplemental Figure 4: Forrest Plot for association of rs12454712 (BCL2) with the ISI in Model 1 and Model 2 of the 
discovery and replication cohorts.  
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Supplemental Figure 5: Forrest Plot for association of rs10506418 (FAM19A2) with the ISI in Model 1 and Model 2 of the 
discovery and replication cohorts  
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 Supplemental Figure 6: Locus Zoom plot for associations at rs12454712 (BCL2)  
 
The LocusZoom plot (1) is shown for rs12454712 (BCL2) and other SNPs within 1MB for association with ISI in 
Model 3 (adjusted for age, sex, and BMI and tested the interaction between genotype and BMI) in the discovery 
cohorts. GWAS catalog traits are presented at the bottom and those traits with a genome-wide significant association 
(P<5×10
-8
) are marked with *. The green horizontal line indicates P=5×10
-8
 and the blue horizontal line indicates 
P=1×10
-7
.  Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer 
CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26:2336-2337 
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Supplemental Figure 7: Locus Zoom plot for associations at rs10506418 (FAM19A2) 
 
The LocusZoom plot (1) is shown for rs10506418 (FAM19A2) and other SNPs within 1MB for association with ISI 
in Model 3 (adjusted for age, sex, and BMI and tested the interaction between genotype and BMI) in the discovery 
cohorts. GWAS catalog traits are presented at the bottom and those traits with a genome-wide significant association 
(P<5×10
-8
) are marked with *. The green horizontal line indicates P=5×10
-8
 and the blue horizontal line indicates 
P=1×10
-7
. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis GR, Willer 
CJ. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26:2336-2337 
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